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Abstract 
 
Glioblastoma multiforme (GBM) are aggressive brain tumors found in the nervous 
system of humans.  Derived from glia such as astrocytes, oligodendrocytes and Schwannn cells, 
glioblastomas can develop throughout the nervous system, but are most commonly found in the 
brain. Prognosis following glioblastoma diagnosis is often very grim; only 3-5% of patients 
diagnosed with glioblastoma live beyond 36 months, therefore early detection and proper 
treatment are imperative. Scientists have studied the genetic factors linked to GBM development 
in humans and model organisms and determined a number of glioblastoma GOI. Many of the 
glioblastoma GOI have been previously identified as oncogenes such as MET, PDGFR and 
EGFR, or tumor suppressor genes such as PTEN, NF1 and p53 whose expression has been 
altered.  
In this study, glioblastoma GOI query sequences from humans, canines, mice and rats 
were aligned with associated chromosome sequences amongst these species in order to determine 
how conserved GOI sequences were across genomes. Using a combination of BLAST algorithms 
such as NCBI’s BLASTn and Blast-Off, which was written for the purpose of this study, both the 
gapless and optimized gapped alignments of each GOI sequence against the subject chromosome 
sequence were determined and scored. Across all 3 model organisms, there was relatively low 
gapless sequence conservation, however scores often improved drastically with the introduction 
of gaps and extensions. There were only 3 human GOI that showed higher than 10% gapless 
alignment when queried against the subject chromosome sequences: CHIC2, MET and MYCN. 
The most highly conserved GBM GOI sequences were MET, EGFR and MYCN; all 3 sequences 
were at least 15% conserved across more than 1 model organism. It is unknown what functional 
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regions may be located within the conserved gene sequences, however identification of these 
conserved regions may help scientists better understand genetic changes associated to 
glioblastoma.  
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1. Introduction 
 
Glioblastomas result from the proliferation of glial tumors in the nervous system of 
humans. Due to their aggressive nature and poor prognosis, scientists have turned to genetic 
research to better understand the development of these tumors in order to find more effective 
treatments. By identifying a number of genes linked to glioblastoma development in humans, 
scientists are able to better understand what genetic changes may occur during tumorigenesis. In 
addition to identifying glioblastoma-related genes in humans, scientists have identified genes 
linked to glioblastoma in a number of model organisms. By identifying shared glioblastoma GOI 
sequences between model organisms, scientists can gain a better understanding of the genetic 
factors linked to tumorigenesis and use these organisms to find better treatment in order to 
improve human GBM prognoses. Although the genes linked to glioblastoma across model 
organisms and humans may differ, many of these genes share similar functionality in addition to 
the conservation of sequence patterns. Therefore there may be conserved sequences that are 
linked to glioblastoma development across model organisms and humans.  
 
2. Background 
 
Glial Cells  
 
Glia are nervous system cells associated with tissue structure and signaling. Glial cells 
can be subdivided into a wide variety of cells found throughout the entire nervous system and 
therefore play an important role throughout the body. There are several types of glial cells, but 
Page 8	  
the 3 major types are astrocytes and oligodendrocytes, which are found in the central nervous 
system, and Schwann cells in the peripheral nervous system (Jessen, 2004). Astrocytes are the 
most abundant type of neuroglial cells. Astrocytes have many different functions including 
playing a role in the development of brain micro-architecture, homeostasis and substrate balance, 
and synapse development and maintenance.  Oligodendrocytes and Schwann cells are not as 
abundant as astrocytes but work together in myelin formation (Kettenmann and Verkhratsky, 
2013).  
Astrocytes were among the first glial cells identified in the early 20th century. Using a 
novel gold chloride staining method developed by Santiago Ramon-y Cajal, scientists were able 
to identify the origins of astrocytes from radial glial cells (Kettenmann and Verkhratsky, 2013). 
Astrocytes are not support cells; rather they work in conjunction with virtually all other cells in 
the central nervous system to diversify cell signaling. In particular, astrocytes work directly with 
neurons to broaden the cell-to-cell signaling between neurons (Ransom and Ransom, 2012). 
When neurons reach their action potential, they release vesicular glutamate compounds that have 
complementary receptors on a downstream neuron. Astrocytes surround the glutamate receptors 
and help push the signaling downstream faster by releasing calcium around the neurons, 
potentially changing the concentration gradient thus releasing more glutamate. Astrocytes can 
not only provide structure and function on their own, but also communicate and catalyze 
signaling from other neural cells (Ransom and Ransom, 2012).   
According to a paper from Brasdl and Lassmann, the majority of scientific discovery and 
understanding of oligodendrocytes is from research on laboratory mice and their central nervous 
system (2009). Oligodendrocytes are also support cells to the myelin sheets found throughout the 
brain and spinal column. Just as astrocytes have many sub-types, oligodendrocytes start as 
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oligodendrocyte precursor cells (OPCs). Depending on the location of the OPCs in relation to the 
surrounding cell types, OPCs may differentiate into either myelin-producing oligodendrocytes or 
protein-expressing OPC populations (Brasdl and Lassmann, 2009). Unlike astrocytes, 
oligodendrocytes have the most interactions with axons through myelin sheath formation; loss of 
the oligodendrocytes (and subsequently myelin formation) is a main characteristic of many 
debilitating nervous system diseases such as multiple sclerosis and the leukodystrophies (Liu and 
Zhou, 2013). Oligodendrocytes will often facilitate cell-to-cell interactions, strengthen cell 
signaling across other OPCs, and are critical in the development of a proper central nervous 
system in humans and model organisms. 
Schwann cells are similar to the oligodendrocytes as they surround large axons and 
produce myelin sheaths around them to help accelerate cell signaling. However Schwann cells 
are not located in the central nervous system, rather they are found throughout the peripheral 
nervous system and are characterized by their ability to differentiate and dedifferentiate rapidly 
(Jessen and Mirsky, 2010). When large axons are present in a population of Schwann cells, they 
produce myelin to support the cell signaling or in the case of injury or lack of large axons, 
dedifferentiate to allow for the development and growth of axons to re-myelinate. The 
differentiation and dedifferentiation of Schwann cells allows for different functionality 
depending on the location of Schwann cells in the peripheral nervous system (Whitlon, Tieu and 
Grover, 2010). All 3 of the major glial cell types have unique functionality throughout the entire 
nervous system and are critical in maintaining homeostatic functionality in the body; any 
inhibition or over activation of these cells can result in pathogenic effects.  
 
Glioblastomas 
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Glioblastomas are tumors that develop from mutated glial cells (gliomas). Just as there 
are many sub-types of glial cells, there are sub-types of glioblastomas such as astrocytomas, 
astroblastomas, oligoastrocytomas and Schwannomas. Astroctytomas are one of the most 
common forms of glioblastomas, found in adults and children alike. They are one of the only 
tumor types that develop in the brain and do not typically metastasize but rather they proliferate 
locally and will often reoccur even after treatment (Stupp, Reni, Gatta, Mazza and Vecht, 2007). 
Astroblastomas are a less common tumor type of mutated astrocyte glial cells, typically found in 
young adults in the head and neck region (Unal, Kiksal, Vjtal, Toy, Kocagullar and Paksoy, 
2008). Oligoastrocytomas (also classified as oligodendrogliomas) are an uncommon hybrid of 
mutated astrocytes and oligodendrocytes. These tumors show characteristics of each mutated cell 
type and therefore can be more difficult to treat (Krouwer, van Duinen, Kamphorst, Valk and 
Algra, 1997). Schwannomas are less common than the astroblastomas and oligoastrocytomas and 
develop from the Schwann cells. Other types of gliobastomas such as giant cell GBMs and 
gliosarcomas only make up <10% of the remaining GBMs and their characteristics and 
functionality are less well known (Miller and Perry, 2007).  
Astrocytomas are one of the more understudied cancers of the central nervous system, 
though they account for nearly 20% of all central nervous system tumors in children. The high-
grade astrocytomas are hyper-cellular with fibrillary cytoplasm and elongated nuclei, which can 
then degrade to areas of necrosis alongside vascular proliferation (Rakopoulos and Hawkins, 
2014). In addition to the histological confirmations of astrocytomas, there are aberrations in 
signaling pathways such as those involving tyrosine receptor kinase and RAS. These signaling 
disruptions are very frequent in astrocytomas (70-90%) however the disruptions can be found in 
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any glioblastoma sub-type (Song et. al, 2013). In addition to their aggressive and disruptive 
nature, astrocytomas can spontaneously progress to anaplastic astrocytomas that lowers 
prognosis outcome greatly.  
Astroblastoma tumors are characterized by elongated and hyperchromatic nuclei and a 
loose, fibrillary matrix. Often times these tumors will also contain mucin-filled cystic spaces in 
the cells, causing abnormal or expanded profiles (Miller and Perry, 2007). The high-grade 
tumors are classified by rapid vascular proliferation and mitotic events, which in turn develop 
regions of high cellular density. (Unal, Kiksal, Vital, Toy, Kocagullar and Paksoy, 2008). The 
lower grade tumors only show simple characteristics such as elongation and vasculations, 
however as the tumors develop further, their features become sporadic and defined (Miller and 
Perry, 2007).  
Schwannomas are the result of mutated Schwann cells, which are located throughout all 
of the peripheral nervous system. Schwann cells are highly versatile nerve cells that are 
concentrated in areas around the face, neck, back, extremities and even some organs. In rare 
cases schwannomas can arise from nerve plexuses around the organ systems like the pancreas 
(Kuo et. al, 2012). The Schwannoma tumor is characterized by firm neoplasms composed of 
undifferentiated glial cells and Schwann cells (Kataria, Kurmi, Mehta and Sinha, 2012). Often 
times Schwannomas can be very difficult to detect due to the tissue density of the brain and 
removal is often times too dangerous. Schwannomas have been directly linked to immature and 
undifferentiated Schwann cells, however the specific conditions necessary for Schwannoma 
development is still misunderstood (Tryggvason, Barnett, Kim, Soken, Maley and Hansen, 
2012).  
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As of late 2013 the median survival rate for patients diagnosed with GBM with standard 
treatment procedures is 15 months, with only 3-5% of patients surviving beyond 36 months after 
diagnosis (McNamara, Sahebjam and Mason, 2013). As with any cancerous tumor, early 
detection can help to vary survival rates, therefore understanding of the morphological features, 
genetic triggers and phenotypic responses to treatment are absolutely critical to improving 
survival rates. The most recent advancements in treatment and understanding come from the 
Cancer Genome Atlas datasets. New clinical tests have revealed that there is genetic significance 
between specific microRNAs and longer survival rates in GBM patients (Qiu, Lin, Hu, Feng, 
Tan and Peng, 2013). There is clear evidence of genetic factors affecting the development of 
glioblastomas; by further exploring the genetic changes that occur in GBMs scientists may be 
able to find more effective means of treatment and prevention. 
 
Glioblastoma-related Genes 
 
In a study by Tae-Min Kim and his coworkers (2013), 8000 human cancer genomes were 
studied for chromosomal alterations to determine if there are reoccurring alterations between 
tumor types. Throughout this study, many tumor types shared gene alterations including genes 
found in glial cells. Compared to breast, lung, and leukemic tumors, GBMs had the highest 
number of gene amplification peaks than any other tumor type.  The consensus genes identified 
in the 8000 human cancer genomes that were related to GBMs were: HOXC13, FGFR3, 
PDGFRB, FANCA, ASPSCR1, CCND1, CDK4, FOXO1, EGFR, CHIC2, MYCN, STK11, 
CRTC1, RECQL4, PAX5, and NOTCH1. The minimum P-value significance of this set 
according to Tae-Min Kim and his coworkers (2013) is 0.458, which gives scientists a list of 
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significant genes of interest across different chromosomes. Although not all of these genes may 
have significant correlation to GBM development, these genes have direct correlations to 
multiple cancer genomes and therefore require further investigation.  
In order to better understand the genetic changes associated with glioblastoma 
development, copy-number alterations should also be considered. Due to the number of genes 
related to support glial cell tumors, it is difficult to determine which specific genes play a 
significant role in glioblastoma development. Across the entire genome, 28 events associated 
with GBM development have been identified (Beroukhim et al., 2007). There are 16 broad 
events and 16 focal events (4 of the focal events fall within the broad events) including 
amplification, deletion and loss of heterozygosity spanning chromosomes 6 through 22.  
 
Figure 1. Significant broad and focal copy-number alterations in the glioma genome. This figure shows the most 
significant of the amplification and deletion events found from human glioblastoma cells (Beroukhim et al., 2007). 
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Although the broad events are spread across a number of chromosomes, the events on 
chromosome 7 and 10 affect >80% of all primary GBMs (Beroukhim et al., 2007). Within the 
copy-number events on chromosome 7 there are 2 main genes of interest related to glioblastoma: 
MET and EGFR. Additionally there is 1 main gene of interest related to the copy-number events 
on chromosome 10: PTEN (Beroukhim et al., 2007). Each event by itself has relations to 
multiple tumor types, but the overlapping events create entirely new effects on human glial cells 
(Beroukhim et al., 2007). 
 
GBM-related Genes – Function and Expression 
 
 When looking at genes of interest relating to tumor development, it is important to 
consider both function and expression. Functionally, many of the genes of interest linked to 
glioblastoma are related to cell signaling, cell differentiation and homeostasis. However when 
genes of interest are expressed differently, their functions can change, leading to susceptibility to 
tumor development. Expression of GBM-related genes falls under 2 types of expression 
anomalies: overexpression and loss of function. Depending on the location of the gene within the 
genome, one type of expression may be favored over the other (Beroukhim et. al, 2007). In the 
case of chromosome 7, the genes MET and EGFR tend to be overexpressed; in the case of 
chromosome 10, PTEN tends to have loss of function. 
c-MET (MET) is a tyrosine kinase dependent receptor expressed in the epithelial cells of 
many tissue types.  The MET signaling pathway is responsible for relaying chemical signals 
from the extracellular matrix to the cytoplasm of a cell (Organ and Tsao, 2012). MET is 
activated from the hepatocyte growth factor (HGF) ligand to help signal proliferation and 
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growth. When HGF binds to the c-MET receptor, two tyrosine residues become phosphorylated 
and can help promote cell proliferation, motility and cell cycle progression (Organ and Tsao, 
2012). In the case of injury to major organ systems such as the kidneys, liver or heart, the HGF 
ligands are up-regulated; this positive-feedback loop suggests that MET is a homeostatic 
pathway that protects and repairs damaged tissue (Peruzzi and Bottaro, 2006). MET is a proto-
oncogene, where regular expression of the MET gene helps normal cell function, but cells can 
become malignant if MET or MET’s ligand HGF becomes overexpressed. The initial linkage of 
MET to cancer was found in 2003 when patients with papillary renal cell carcinomas shared a 
missense mutation of the MET gene (Jung, Park and Hong, 2012). In the case of human 
glioblastomas, the overexpression of HGF and the MET pathway may contribute to tumor 
growth by blocking apoptotic signals and forcing cell dissociation (Appleman, 2011). There are 
multiple mutations attributed to the oncogenetic properties of the MET pathway, such as 
overexpression of the HGF promoter region or direct overexpression of receptor proteins in the 
MET pathway (Jung, Park and Hong, 2012). Under constant ligand stimulation, the MET 
pathway will force motility to dissociated cells, which can lead to metastasis in humans (Peruzzi 
and Bottaro, 2006). 
EGFR or epidermal growth factor receptor is a gene responsible for cell signaling across 
cell membranes, such as oligodendrocytes (Wang, Shu-Mei Huong et al., 2003). Similar to the 
MET pathway, the EGFR is also a tyrosine kinase dependent receptor, whose pathway is 
responsible for growth factors such as transforming growth factor alpha (TGF-α) (Nicholson, 
Gee and Harper, 2001). When properly functioning in humans, the EGFR is responsible for 
phosphorylation of tyrosine residues, which in turn aid in intracellular communication and cell 
differentiation. Throughout the past decade, there has been extensive research performed on the 
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structure and basic functions of EGFR. There are two major conformation types of EGFR 
identified, the active conformation responsible for cell signaling and the inactive conformation as 
seen in members of the Src family of kinases (Eck and Hahn, 2012). The amount of time EGFR 
is in its activation conformation is highly regulated by the chemical signals around the cell. In a 
healthy individual, the activation and deactivation is discrete, however when EGFR becomes 
mutated, it enters a third, disordered state that does not deactivate (Eck and Hahn, 2012). 
Mutated EGFR is simply one example of the devastating effects of overexpressed protein kinase 
and has been linked to numerous gain-of-function cancers. 
The PTEN, or phosphatase and tensin homolog deleted on chromosome 10, is a negative 
regulator gene and tumor suppressor (Chow and Baker, 2006). The PTEN gene when functioning 
properly is responsible for directly suppressing the oncogene PI3K, which is in turn responsible 
for signaling survival, growth and proliferation in the cell. The PTEN gene received its name 
through its identification on chromosome 10 in a loss of heterozygosity region often mutated in 
patients with high-grade tumors (Chow and Baker, 2006). PTEN is a gene responsible for the 
creation of lipid phosphate, which is used to regulate cell stimulation from the PI3K stimuli 
(Chow and Baker, 2006). When mutated with either missense or nonsense mutations, the PTEN 
gene becomes deactivated and allows for cell proliferation to continue without negative 
feedback. On average, patients diagnosed with high-grade glioblastomas showed mutations of 
the PTEN gene 20-40% of the time (Baeza, Weller, Yokenawa, Kleihues and Ohgaki, 2003).  
 
GBM in Model Organisms 
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Due to the aggressive nature of glioblastomas in humans, research has been slow and 
often patients will pass away before studies can be completed. In order to conduct more robust 
research on glioblastoma and its development, scientists have turned to model organisms. There 
are 3 main types of model organisms used in glioblastoma research: chemically induced models, 
genetically engineered mice (which may be virally induced as well) and xenograft models 
(Huszthy et. al, 2012). The first two types have been directly linked to genetic factors whether 
artificially or naturally and are used when comparing genetic factors in human glioblastoma 
development. The third model, the xenograft model, is the transplantation of live human tumor 
cells into another species; this model may be phenotypically similar to human GBM 
development, but does not give the scientist information on genetic factors of glioblastoma 
within the model organism. Any organism used for brain tumor research will typically fall within 
these 3 categories, but in order for them to be useful in GBM research, they must meet stricter 
criteria. Generally for a model organism to be useful for glioblastoma research it must meet the 
following 8 criteria (Barth and Kaur, 2009): 
 
1. The model must have a brain tumor derived from glial cells. 
2. They should be able to have tumor cells able to grow and clone in vitro as 
continuous cell lines. 
3. The tumor growth rates should be both predictable and reproducible. 
4. The tumors should have human glioma-like growth characteristics within the 
brain.  
5. Host survival following a tumor implantation should be of a sufficient duration to 
allow for therapy and research. 
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6. For therapy, the tumor should be weak or non immunogenic in xenographic hosts. 
7. The tumors should not metastasize beyond the brain. 
8. The reaction to treatments should be predictive to the human brain tumor. 
 
By using model organisms that follow this criterion, scientists can confidently use this data to 
better understand the development of human glioblastoma. As of 2014, there have been 4 model 
organisms that have fit these scientific criteria and provided scientists with valuable genetic 
information on glioblastomas – mice, dogs, rats and cats.  
The most common model organism used in glioblastoma research has been mice. Unlike 
human glioblastoma development, glioblastomas in mice often lack tumor penetration and 
therefore glioblastoma induction is often achieved through direct mutation of tumor-suppressor 
genes or overexpression of oncogenes. (Reilly, Loisel, Bronson, McLaughlin and Jacks, 2000). 
Although induction may vary, many of the characteristics of human GBMs such as 
hemorrhaging, tumor necrosis followed by viable tumor cells, and vascular proliferations were 
observed in mouse GBM. Alongside of the direct induction of astrocytomas in lab mice, there 
was secondary tumor development seen in mice as brain lesions in varying degrees, which would 
further proliferate into glioblastomas (Holland, Celestino, Dai, Schaefer, Sawaya an Fuller, 
2000).  
Unlike mice, the canine model can naturally develop glioblastoma without induction. 
Additionally, canine GBM occur typically in middle-aged dogs (>6 years) rather than human 
GBM, which occur more frequently in children and young adults (Debinski, Dickinson, 
Rossmeisl, Robertson and Gibo, 2013). In a study performed in 2007, the pathological features 
of glioblastoma across dogs, rodents and humans were compared. Just as mice and humans 
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showed tumor necrosis and hemorrhaging, the canine glioblastoma also expressed the same 
features. However, unlike the mice and human glioblastoma tumors, canine GBMs exhibited 
endothelial proliferation during glioblastoma development (Candolfi et. al, 2007). Although 
canines may spontaneously develop glioblastomas, it is still a very rare disease to occur naturally 
(<2% of all tumors found in canines) (Debinski, Dickinson, Rossmeisl, Robertson and Gibo, 
2013). Often times astrocytoma tumors will be implanted within dog models due to the low rate 
of occurrence in nature. By implanting canine astrocytoma cells in fetal dogs prior to its 
developing immune competency, scientists are able to develop solid brain tumors that express 
the same pathological features (Berens, Giese, Shapiro and Coons, 1999). Using this method, 
scientists can study GBM development and treatment in the canine model organism without 
subjecting the model organism to radical induction procedures that could compromise the 
subject.  
Possibly the oldest model organism for glioblastoma research is the rat. Chemically-
induced glioblastoma rat models have been used as glioblastoma model organisms for over 30 
years (Huszthy et. al, 2012). In a study published in the early 1970’s, scientists were able to 
reproducibly induce central nervous system tumors in rats through	   multiple	   doses	   of	   N-
methylnitrosourea (MNU) or a single dose of N-ethyl-N-nitrosourea (ENU) (Barth and Kaur, 
2009). In addition to the chemical induction of brain tumors, rats can spontaneously develop 
glioblastoma just as canines and humans, although the occurrence is much more rare. (Huszthy 
et. al, 2012). One major advantage of the rat model compared to that of the mouse model is the 
size of the rat brain; the larger brain allows for more direct, accurate tumor manipulation. In the 
mouse model, on the other hand, it is far easier to manipulate the genetic factors and 
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environmental factors that give scientists better understanding of the pathways involved in 
glioblastoma development (Barth and Kaur, 2009).   
The final model used in genetic research on glioblastoma development is feline. 
Compared to canines and rodents, felines are not frequently used as model organisms due to the 
rarity of central nervous system tumors (Barth and Kaur, 2009). In felines with neoplasms 
(tumorous precursors) in the central nervous system, only 2.8% of the cranial neoplasms and 
3.5% of spinal neoplasms are linked to glioblastoma (Aloisio, Levine and Edwards, 2008). 
Therefore the genetic characteristics linked to feline glioblastoma development are varied. In a 
recent study, the histological features of feline neoplasm were compared to other neoplastic 
historical data of human GBMs. Scientists found that histological features such as asymmetrical 
nuclei, fibrin matrices, tumor invasion and hemorrhaging, which were identified in human 
glioblastoma tumors, were also seen in feline GBM development (Hammond, deLaunta, Glass, 
Kent, Summers and Miller, 2014).  
 
GBM-related Genes in Model Organisms 
 
Just as genes have been linked to glioblastoma development in humans, there are a 
number of genes linked to glioblastoma development across the 4 main model organisms. 
Similar to human glioblastoma development, there are multiple pathways linked to glioblastoma 
in model organisms.  
In genetically engineered mice, glioblastoma have been induced through the progression 
of astrocytoma (called secondary GBM) as well as the direct de novo induction (primary GBM) 
(Kamnasaran, Qian, Hawkins, Stanford and Guha, 2007). One of the de novo means of inducing 
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GBM in mice is through the overexpression of the oncogenetic Ras pathway. The Ras pathway, 
like the EGFR or MET pathways, is a signaling pathway used within the cells themselves. When 
both Ras and the complementary signaling pathway Akt are overexpressed in lab mice, 
glioblastoma tumors develop with similar histological features to human GBM (Holland, 
Celestino, Dai, Schaefer, Sawaya and Fuller, 2000). Although the Ras and Akt pathways are not 
directly linked to GBM development in humans, when testing human GBM samples, there are 
Ras and Akt proteins found in the extracellular matrix (Holland, Celestino, Dai, Schaefer, 
Sawaya and Fuller, 2000). Another means of inducing GBM tumors in mice is the suppression of 
neurofibromatosis type 1 gene (NF1) and Trp53 gene, located on chromosome 11 in mice (Reilly 
et. al, 2004). Similar to the PTEN suppression seen in human GBM development, the NF1 
suppression blocks the negative feedback of Trp53 stimuli resulting in overexpression of the 
oncogenes. Unlike the Ras/Akt glioblastoma induction, where GBMs are developed from 
astrocytomas in the brain, the NF1-suppressed glioblastomas are developed in the eye or ocular 
nerve (Reilly et. al, 2004). This allows for the mouse model to develop glioblastomas from two 
different regions of the central nervous system, thus making genetically engineered mice a better, 
more robust model for glioblastoma. 
In the canine model, although human and canine GBM can both develop spontaneously, 
the pathways responsible for GBM development can differ. In a paper from 2012, the p53 tumor 
suppressor gene, commonly associated with many tumorigenesis pathways in humans, especially 
astrocytomas, was sequenced for mutations across 88 canine brain tumors, 18 of which were 
astrocytic. Across all 88 brain tumors, only 4 tumors showed p53 mutation (1 of the astrocytic 
tumors tested positive for p53 mutation), which is a significantly less mutation rate than human 
brain tumors (York et. al). The results of the paper suggests that p53 may play a role in a very 
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small number of canine GBMs, or it may act as a catalyst in GBM development from other 
pathways. One of the shared pathways linked to GBM in humans and canines is the EGFR 
pathway. In roughly 60% of all canine glioblastomas, EGFR and other tyrosine kinase receptors 
like PDGFR are up-regulated (Higgins et. al, 2009). Similarly, the IGFBP2 gene, which is 
responsible for the expression of the Ras/Akt pathway in mice, is also found in most high-grade 
canine glioblastomas (Higgins et. al, 2009). The combination of shared pathways between the 
genetically engineered mice and humans suggests that the canine model is a good translational 
model between the genetically induced glioblastomas created in the lab and the spontaneous 
glioblastomas arising in nature. 
The rat brain tumor model is the oldest of all glioma model organisms, and has been used 
in glioma studies for decades. There are a number of rat brain tumor models such as 9L, C6, T9, 
F98, RG2, RT-2 and CNS-1, all created through different induction techniques (Barth, 1998). 
Although most of the chemical induction techniques have been around for years, recently a 
number of the genes responsible for inducing glioblastomas in rats have been identified. Across 
the C6, 9L, F98 and RG cell lines there were hundreds of overexpressed and under-expressed 
genes compared to the rat control groups (Sibenaller et. al, 2005). Although there were hundreds 
of genes identified, only a small number have significantly higher rates of overexpression. Many 
of the growth factor genes such as EGFR and IGF-1 and NGF were overexpressed in the rat cell 
lines. Similar to the canine model, the p53 tumor repressor gene was expressed at similar levels 
across all cell types, including the control groups (Sibenaller et. al, 2005). In addition to the 
overexpression of growth factor genes, there was overexpression of the D1 cyclin found in most 
of the rat cell lines, especially in the C6 line, which most closely resembles adult GBM 
(Sibenaller et. al, 2005). Cyclin D1 is a protein complex that is responsible for the progression of 
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the cell cycle through G1. In the case of rat gliomas, there are higher levels of mRNA and cyclin 
proteins resulting in abnormal cell proliferation (Cavalla, Dutto, Riva, Richiardi, Grosso and 
Schiffer, 1998). Although rats may not spontaneously develop glioblastomas, unlike canines and 
humans, the rat model shares many of the genetic features found in human glioblastomas. In 
addition to the similarity to human GBM, the variety of rat models allow scientists to compare 
rates of expression across the different cell lines, making the rat a good model for comparing and 
contrasting genetic expression in glioblastomas.  
The feline is the most recent of the model organisms used in glioblastoma research. 
Contrary to the GBM research on canines, rats and mice, little genetic data is available for other 
domesticated animals such as felines (Aloisio, Levine and Edwards, 2008). Most of the genetic 
research on feline brain tumor development has been on meningioma, which may be due to the 
fact that 85% of all feline brain tumors are meningiomas and not gliomas (Motta, Mandara and 
Skerritt, 2011). Although there is limited research on feline glioblastoma, many times the feline 
and canine models are used together due to their similar mechanisms of tumorigenesis compared 
to the human model (Johnson, Coates and Wininger, 2013). The most researched gene associated 
to tumorgenesis in feline brain tumors has been the p53 tumor suppressor gene. Unlike the 
canine and rat models, mutation and suppression of the p53 gene has been linked to a number of 
feline cancer types. In a 2000 study of feline tumors, p53 mutation was screened across 486 
neoplasias. Compared to canines and rats, there was immunopositivity for p53 in all neoplasia 
except in malignant lymphomas and fibrosarcomas (Nasir, Krasner, Argyle and Williams, 2000). 
Therefore, loss of function mutations may exist in feline gliomas, similar to the PTEN 
suppression observed in human gliomas. Although there is evidence that supports spontaneous 
glioblastoma development within felines, there are no papers (at the time of writing this thesis 
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project) directly linking glioblastoma to genes of interest within the feline model. Therefore for 
the purpose of this project, only canine, rat and mice models will be used in determining 
conserved GBM gene of interest sequences between humans and model organisms. 
 
3. Materials and Methods 
 
Genes of Interest Sequence Data 
 
There are a number of genes of interest across humans, mice, rats and canines that will be 
used in this study to determine consensus sequences. The mRNA sequences for each gene were 
retrieved from the nucleotide database through the National Center for Biotechnology 
Information (NCBI) website. The NCBI nucleotide database contains sequences from multiple 
sources including GenBank and RefSeq. For the purpose of this study, the FASTA sequence 
standard will be used. Although there are next generation sequencing technologies available, 
many with their own sequence formats, FASTA is the de facto standard when utilizing multiple 
bioinformatics tools (Waldmann, Gerken, Hankeln, Schweer and Glockner, 2014). The genes of 
interest were all downloaded in FASTA format and saved as text files. Whenever there were 
multiple transcript variants available for a given gene, the first variant was used. The genes of 
interest for this study, sorted by organism, are outlined as follows: 
	   Gene	   Accession	  No.	   Chromosome	  Location	   Size	  (bp)	  
H.	  sapiens	  
PTEN	   NM_000314.4	   10q23.3	   5572	  
MET	   NM_001127500.1	   7q31	   6695	  
NOTCH1	   NM_017617.3	   9q34.3	   9309	  
PAX5	   NM_016734.2	   9p13	   8909	  
RECQL4	   NM_004260.3	   8q24.3	   3840	  
CRTC1	   NM_015321.2	   19p13.11	   6961	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STK11	   NM_000455.4	   19p13.3	   3286	  
MYCN	   NM_001293228.1	   2p24.3	   3046	  
CHIC2	   NM_012110.3	   4q11	   1178	  
EGFR	   NM_005228.3	   7p12	   5616	  
FOXO1	   NM_002015.3	   13q14.1	   5738	  
CDK4	   NM_000075.3	   12q14	   2020	  
CCND1	   NM_053056.2	   11q13	   4304	  
ASPSCR!	   NM_024083.3	   17q25.3	   1858	  
FANCA	   NM_000135.2	   16q24.3	   5460	  
PDGFRB	   NM_002609.3	   5q33.1	   5718	  
FGFR3	   NM_000142.4	   4p16.3	   4304	  
HOXC13	   NM_017410.2	   12q13.3	   2435	  
M.	  musculus	  
HRAS	   NM_008284.2	   7	   2043	  
AKT1	   NM_009652.3	   12	   2707	  
NF1	   NM_010897.2	   11	   11847	  
TRP53	   NM_011640.3	   11	   1781	  
C.	  lupus	  
TP53	   NM_001003210.1	   5	   1174	  
EGFR	   XM_533073.4	   18	   6006	  
PDGFRA	   XM_005628195.1	   13	   6234	  
IGF2	   NM_001195825.1	   18	   1095	  
R.	  norvegicus	  
IGF1	   NM_001082477.2	   7	   1582	  
EGFR	   NM_031507.1	   14	   4161	  
CCND1	   NM_171992.4	   1	   3809	  
NGF	   NM_001277055.1	   2	   1075	  
Table 1: Glioblastoma genes of interest from humans, mice, dogs and rats. The accession numbers correspond to 
NCBI sequences related to the genes of interest. 
 
There are multiple growth factor genes of interest shared between the model organisms, although 
they may be located on different chromosomes. In this study, growth factor genes such as EGFR 
and PDGFRA will be aligned across model organisms to find consensus sequences regardless of 
chromosomal location. Using a sequence alignment algorithm, multiple gene sequences such as 
the growth factor genes of interest, can be compared to determine consensus sequences. These 
sequences can then be searched against model organism genome maps to determine location. 
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NCBI BLAST Program 
 
The Basic Local Alignment Search Tool (BLAST) is an algorithm created in 1990 and 
designed to align a (shorter) query sequence against a database of sequences using a heuristic 
approach (Altschul, et. al, 1990). The BLAST program utilizes a multistage approach to quickly 
and exhaustively search for matches between the query sequence and the database.  Many of the 
stages within the BLAST program have been performance improvements to the overall 
algorithm, each implemented individually to keep the BLAST program efficient with growing 
sequence data in databases like GenBank (Cameron and Williams, 2007). However there are 4 
major stages within the BLAST algorithm which are needed to properly identify optimal 
alignment between the query sequence and sequences within the database. Prior to the first stage 
of the BLAST algorithm is sequence conversion from FASTA to bytepack representation of each 
sequence. Initially, sequences processed in the BLAST tool were in FASTA format in which 
each nucleotide was represented by a string character (which would be 1 byte in 8-bit ASCII 
encoding). However, by converting a nucleotide into a 2 bit representation, such as the ones seen 
in Figure 2, a single byte can store 4 nucleotide bases, saving space in memory and limiting disk 
usage time (Cameron and Williams, 2007).  
 
 
Figure 2: Bytepack representation of the sequence ATGACATGCG. The resulting representation of the nucleotide 
sequence is a fraction of the original size when stored in memory (Cameron and Williams, 2007). 
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Once the sequences have been converted to the 2-bit representation, the BLAST program starts 
the first stage of the algorithm. The first stage is converting the database sequences and query 
sequences into words. These words are a fixed size subunit of a nucleotide sequence, which are 
then stored in a lookup table such as a HashMap or Dictionary. The query sequence is also 
processed into n-sized words that are compared to the lookup table for very rapid association 
between the query sequence and database (Cameron and Williams, 2007).  Once the words are 
compared and matches are made, the locations of these matches are stored and the BLAST 
program moves to stage two. The second stage of the BLAST algorithm utilizes the matches 
found in the first stage. These matches are then extended in each direction, scoring for matches 
and mismatches until the sequence pair falls below a score threshold. The runtime and 
computation demand can vary highly, depending on how similar the sequences are between the 
query and database (Cameron and Williams, 2007). In the third stage of the BLAST algorithm, 
the ungapped alignments determined in stage 2 are passed through a dynamic programming 
algorithm to introduce gap extensions. By using affine gap penalties, the best alignment between 
a query word and its aligned pair within a database can be determined. Additionally, introducing 
gaps increase the likelihood that other aligned words will overlap, allowing for a new maximum 
gapped alignment. Finally, the fourth stage is the reporting of the significant gapped alignments 
using traceback. In order to determine the statistical significance of the alignments through the 
BLAST algorithm, the E-value is calculated. The E-value is a function of the bit score (S’ value) 
where 𝑆! = (𝜆𝑆 − ln𝐾)/ ln 2 and 𝐸 = 𝑛  ×  𝑚 /(2!!) (Kerfeld and Scott, 2011). The variables λ 
and K represent the matrix size and gap penalty, while 𝑛  ×  𝑚  is known as the search space, or 
the size of the query sequence versus the sum of the sequence lengths within a database. The E-
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value represents the number of sequences expected to be retrieved from the database with a 
better bit score than the alignment determined from the subject and query sequence by chance 
(Kerfeld and Scott, 2011). The closer an E-value is to zero, the more sequences samples within 
the database are closely related to the query sequence and therefore the higher the likelihood a 
homolog has been identified from the BLAST algorithm.  
 
Using BLAST to Identify Genome Sequences 
 
The BLAST platform can be used as a standalone program or through a server. The 
BLAST server through NCBI provides users with multiple versions of the BLAST algorithm 
such as PSI-BLAST, BLASTn and BLASTp, each specializing in the alignment of protein or 
nucleotide sequences using heuristic scoring approaches. For the purpose of this study, the 
BLASTn program was used. BLASTn through the NCBI website allows users to search for 
related nucleotide sequences across entire genomic databases for model organisms. Using the 
accession numbers found in Table 1, the BLASTn program was used to query the NCBI database 
to find related gene sequences between humans, mice, rats and dogs.  
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Figure 2: Screenshot of BLASTn program from NCBI database. This is the report page used for query submissions 
through the BLAST program. It includes the related gene accession numbers, their query cover between the two 
sequences and their E-score. 
 
Using the NCBI BLAST program, the glioblastoma genes of interest identified in Table 1 were 
analyzed against the NCBI database to determine the closest nucleotide sequences found in the 
other model organisms.  By identifying the nucleotide sequences with the highest query cover, 
the genes of interest can be loosely linked to the corresponding chromosomes within the 
remaining model organisms. A tabulated format of each gene of interest, their corresponding 
chromosomes across the remaining model organisms, the query cover percent, and the E-value 
can be found in the appendix (Appendices I-IV).  
 
Blast-off Analysis Tool 
 
While the BLAST program through the NCBI database is highly effective when 
searching a query sequence against the GenBank database of nucleotide sequences, the database 
sequences used are a small subset of the complete GenBank database (Cameron and Williams, 
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2007). In order to better understand the comparisons between a query sequence and an associated 
chromosome assembly sequence, a modified BLAST program was written. This new program, 
called Blast-Off, was created as an offline tool to further compare the conserved sequences 
across model organisms. Blast-Off was written in JAVA 7 for its compatibility between 
operating systems, in addition to its simplicity as an object-oriented language. Blast-Off is run 
through java using the command line, and the command to use the program is as follows: 
 
$java Blast_off <gene filepath> <chromosome filepath> <word size> <score threshold> 
 
The Blast-Off algorithm utilizes the first two stages of the BLAST program to calculate the 
gapless, conserved regions between genes of interest and chromosome sequence data. By 
providing Blast-Off with a query sequence and a chromosome sequence (determined by the 
associated sequences through NCBI BLASTn), Blast-Off provides the user with a rapid analysis 
of conserved regions between a gene of interest and its associated chromosome.  
There are a few differences between the Blast-Off algorithm and the NCBI BLAST 
algorithm that provide the user with a more transparent analysis of the gene of interest. As stated 
previously, the Blast-Off algorithm utilizes the first two stages of the multi-step BLAST 
program; unlike NCBI BLAST, Blast-Off only considers gapless alignments and does not use 
dynamic programming for gap extensions. By not considering gap extensions, the user can 
calculate how much a gene of interest is purely conserved within a chromosome of another 
species. Another difference between the two programs is the Blast-Off algorithm can read and 
analyze compressed FASTA sequences for faster loading into memory. By loading compressed 
FASTA files into associative arrays, large sequences such as chromosome sequences can be 
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loaded into memory and accessed quickly while decreasing the impact on disk usage. In 
conjunction with loading the genomic sequences into memory at run-time, there is no need for 
preprocessing the words in a chromosome – the n-sized words can be computed and stored in an 
associative array at run-time in order to minimize complexity of the algorithm and increase 
performance.  
The output of Blast-Off includes the conservation score, determined by the most 
conserved region of the gene of interest across the associated chromosome as well as all high-
scoring pairs determined in stage two.  
Figure 3: Screenshot of the Blast-Off program output. The sample output of the Blast-Off program includes the 
high scoring pairs (HSP) in addition to the conservation score.   
 
As shown in Figure 3, the query and genome (which is a single chromosome as determined from 
BLASTn results) sequences get loaded into memory and are then processed and reported through 
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the console to the user. For the purposes of this study, the gene sequences were loaded into the 
program in FASTA format due to their relatively small size. However, in order to load and read 
the large chromosome sequences into memory, the sequences were compressed using the GZIP 
compression utility. The gene sequences and the chromosome sequences for H. sapiens, M. 
musculus, R. norvegicus, C. lupus were all retrieved through the NCBI FTP site at 
ftp.ncbi.nih.gov. The Blast-Off source code, gene sequences, and compressed chromosome 
sequences for this study can be found at: 
https://sites.google.com/site/blastoffofflineblastutility/ 
 
Using BLASTn to Determine Full Alignment 
 
Using BLASTn to determine the associated chromosomes for each human or model 
organism, Blast-Off was utilized to determine all high-scoring pairs and to extend each HSP in 
order to identify the longest, gapless sequence between a GOI and chromosome. However, it is 
very likely that high-scoring pairs, which were extended without gaps, would become much 
longer when gaps were considered for each extension. Additionally, the Blast-Off utility does not 
account for HSPs, which overlap and therefore could be combined with one another to increase 
the overall score and create a better alignment. For the purposes of this study, achieving the 
optimal alignment for each gene of interest and its associated chromosome was critical in order 
to fully understand how glioblastoma sequences are conserved between humans and the other 
model organisms.  
Instead of using NCBI BLAST against a database to determine corresponding sequences, 
NCBI BLAST can be used between a query sequence and chromosome subject sequence to 
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determine optimal local alignment. As stated before, the BLASTn program accounts for gaps and 
overlapping HSPs to determine optimal local alignments. Additionally, BLASTn recognizes the 
low complexity regions between the query and chromosome sequences and removes them. By 
removing the low complexity regions, the length of HSP may be reduced from the Blast-Off 
results, however the sequence conservation determined through BLASTn will be more 
substantial. The scoring parameters between Blast-Off and NCBI BLASTn utilities differ when 
extending the HSP in either direction. Blast-Off uses much smaller match/mismatch weights for 
the HSP extension due to its inability to omit low complexity regions. Blast-off uses a match 
score of 1 and a mismatch score of -1 and no score for gaps. However, in order to find the 
optimal alignments for the GOI and associated chromosomes, the default values for 
match/mismatch/gaps were used for BLASTn. For the NCBI BLASTn program, matches were 
scored with a +2, mismatches scored a -3, and gaps were penalized with a -2 score. The stricter 
scoring weights for extension allowed for a more selective extension algorithm and thus more 
conserved sequences between the genes of interest and the associated chromosomes. Once the 
sequences were aligned through the BLASTn utility, the alignment with the highest scoring E-
value was recorded. The attributes for each glioblastoma GOI alignment through NCBI BLASTn 
were recorded and can be found in Appendix VII and VIII, while the entire sequence alignment 
for each GOI to the associated subject chromosome sequence can be found in Appendix IX. 
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4. Results and Observations 
 
Query Cover 
 
From the initial search of all genes of interest identified in Table 1, many H. sapiens 
genes showed similar query cover between model organisms. On average, C. lupus shared 54.6% 
query coverage with H. sapiens GOI, while M. musculus shared an average of 56.6% query 
coverage and R. norvegicus shared an average of 51.7% query coverage across H. sapiens GOI.  
 
 
Figure 4: H. sapiens glioblastoma genes of interest query cover across model organisms. The values for each 
BLAST query cover result can be found in Appendix I. 
 
Although the model organism averages are fairly similar, there are some human GOI sequences 
that are found more completely in one model organism over another. PTEN showed 96% query 
coverage within the mouse genome in contrast to the 24% and 21% in canines and rats 
respectively. RECQL4 showed 51% query coverage in canines compared to 24% and 31% in 
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mice and rats. HOXC13 had 97% query coverage in canines, 58% in mice and 44% in rats. 
FOXO1 showed the most discrepancy between all 3 model organisms; there was 95% query 
coverage found in canines, 68% found in mice and 44% found in rats. In contrast to many other 
GOI sequences, MYCN query coverage was low in canines (49%) but the same 81% query 
coverage in mice and rats.   
There were also multiple human GOI sequences that showed similar query coverage in 
all 3 model organisms. EGFR averaged 64.6±1.5% query coverage across all 3 model organisms. 
Compared to other glioblastoma genes of interest, EGFR query coverage was relatively low 
considering the significance of EGFR mutations being linked to a large number of human 
cancers including GBM. In contrast, ASPSCR1, which has been linked to sarcomas in humans, 
but not in other model organisms, showed much higher average nearly 74.6±1.5% query 
coverage in all 3 model organisms. NOTCH1, which was identified by Tae-Min Kim (2013) as a 
GOI for multiple human neurological cancers in addition to a GOI across multiple cancers within 
mice, dogs and rats, showed the highest average query coverage with 86.0±1.7%.  
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Figure 5-8: Glioblastoma GOI query coverage results for canines, mice and rats. The result values for each GOI 
BLAST search can be found in Appendices II-IV. 
 
 
Compared to the human GOI sequences, the GOI sequences for mice, rats and canines 
showed higher average query cover when compared to the human genome. On average, mice 
GOI sequences showed 72.0% query coverage compared to the human genome, canines showed 
even higher average of 84.0% query cover and rats showed the highest average of 89.5% query 
cover. Although these averages may be considerably higher than the human GOI average query 
0%	  20%	  
40%	  60%	  
80%	  100%	  
HRAS	   AKT1	   NF1	   TRP53	  P
er
ce
nt
	  Q
ue
ry
	  C
ov
er
	  
Mus	  musculus	  GOI	  query	  cover	  	  
0%	  20%	  
40%	  60%	  
80%	  100%	  
IGF1	   EGFR	   CCND1	   NGF	  P
er
ce
nt
	  Q
ue
ry
	  C
ov
er
	  
Rattus	  norvegicus	  GOI	  query	  cover	  
Page 37	  
cover, they may be a result of a limited number of genes of interest to test between model 
organisms and the human genome. Additionally, many of the genes of interest tested within each 
model organism have identified homologs within the human genome, while a number of human 
GBM GOI such as ASPSCR1 and FANCA have only been identified as theoretical sequences 
within model organisms.  
In addition to the higher average query coverage, many human glioblastoma GOI are 
shared as model organism GBM GOI, and these genes showed very high query coverage when 
queried against the human genome. Canine EGFR when queried against the human genome was 
77% covered, which compared to the human EGFR to canine genome’s 63% coverage is much 
higher. However, compared to the other canine GOI queried against the human genome, 77% 
coverage was the smallest coverage. The most covered canine GOI was actually platelet-derived 
growth factor receptor alpha (PDGFRA) with 97% coverage within the human genome. 
Although the PDGFR alpha gene was a glioblastoma gene of interest for canines, the PDGFR 
beta gene was a glioblastoma gene of interest for humans. The human PDGFRB showed much 
lower covereage (67%) when compared to the canine genome, although PDGFRB coverage was 
still higher than the average for human GOI. R. norvegicus EGFR queried against the human 
genome showed 97% coverage, which was far more coverage than either canine EGFR to the 
human genome, or human EGFR to the rat genome (66%). CCND1, which is a glioblastoma GOI 
in both humans and rats, was also compared across the 2 organisms. Rat CCND1 compared to 
the human genome showed 68% coverage, which was the lowest coverage of all rat GOI 
compared to the human genome. In the case of M. musculus, there are no shared glioblastoma 
genes of interest with humans. The most conserved glioblastoma GOI in mice was NF1, which 
showed 86% query cover when compared to the human genome. Glioblastoma genes of interest 
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identified in model organisms may or may not be the same genes identified as GMB GOI in 
humans, but it appears that GOI sequences may be conserved in portions across each organism; 
although their expression and significance to cancer development within each species may vary. 
 
Gapless Sequence Conservation 
 
Using the Blast-Off utility to determine the longest “pure” or gapless alignment within a 
query of a GOI against a chromosome, most genes of interest identified in H. sapiens showed 
relatively low gapless sequence conservation. As shown in Appendix V, with the exception of 
the H. sapiens FOXO1 gene aligned to chromosome 25 in C. lupus, which showed 64.8% 
gapless alignment, all other H. sapiens genes aligned to the chromosomes of model organisms 
through Blast-Off showed <20% gapless alignment across the query gene.  
 
 
Figure 9: H. sapiens glioblastoma GOI alignment scores determined through Blast-Off utility. The results of each 
GOI alignment to the associated chromosome sequences of each model organism can be found in Appendix V. 
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Compared to other model organisms, C. lupus showed the highest overall gapless 
alignment with an average of 4.46% of each human GOI sequence conserved purely in the 
associated canine chromosome. M. musculus also showed similar gapless conservation of human 
glioblastoma GOI, on average each human gene of interest had 3.90% gapless conservation 
within the associated mouse chromosome. In the case of R. norvegicus, each human gene of 
interest showed on average 2.13% gapless conservation within the associated rat chromosome.  
Of the human glioblastoma GOI queried through Blast-Off, there were only a few genes 
of interest whose gapless alignment score was much higher than the average for that model 
organism. The CHIC2 gene queried against C. lupus yielded 10.6% gapless alignment and 8.7% 
alignment against M. musculus. The MET gene queried against the canine chromosome 14 
yielded 11.9% gapless conservation, and 7.4% gapless conservation in mouse chromosome 6. 
While the MYCN gene showed low query cover when compared to the canine genome, human 
MYCN showed the highest gapless alignment of all model organisms. Human MYCN gene 
showed 14.3% gapless alignment when compared to the canine chromosome number 17, while 
MYCN only showed 3.2% gapless alignment when compared to mouse chromosome number 12 
and 3.3% when compared to the rat chromosome number 6. PDGFRB gene, which was shown to 
have 56% query cover in the mouse genome, showed 7.1% gapless alignment within the mouse 
chromosome number 18.  
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Figure 10-12: Glioblastoma GOI % pure gapless alignment between model organism gene and its corresponding 
chromosome within the H. sapiens genome. The results of each model organism GBM GOI alignment through 
Blast-Off can be found within Appendix VI. The rough HSP and their alignments can be found within the Blast-Off 
Results folder at https://sites.google.com/site/blastoffofflineblastutility/.	  
 
 
Similar to the human glioblastoma genes of interest, the model organism glioblastoma 
genes of interest have relatively low pure, gapless alignment. Just as the human glioblastoma 
GOI showed the highest average gapless alignment when compared to the C. lupus genome, the 
canine GBM GOI showed the highest average gapless alignment when compared to the human 
genome. On average, the canine glioblastoma genes of interest were 6.7% purely aligned to the 
associated human chromosome. In the case of R. norvegicus, the glioblastoma genes of interest 
for rats showed 6.15% alignment when compared to the associated human chromosome. M. 
musculus showed the least average alignment; on average each GOI showed a gapless alignment 
of 2.36% against the corresponding chromosome.  
Considering the highest alignment across all 3 model organisms, the canine EGFR gene 
showed at most 6.0% gapless alignment when aligned against H. sapiens chromosome 7. 
Additionally the canine PDGFR gene showed at most 1.3% gapless alignment against human 
chromosome 4. Although the canine EGFR alignment was similar to the average gapless 
0	  0.02	  
0.04	  0.06	  
0.08	  0.1	  
0.12	  0.14	  
0.16	  0.18	  
IGF1	   EGFR	   CCND1	   NGF	  
R.	  norvegicus	  GOI	  %	  Pure	  Alignment	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alignment, the PDGFR gene was far less than the gapless alignment average. Looking at the rat 
EGFR gene, rat EGFR showed 11.8% gapless alignment against human chromosome 7, which 
was far higher than the average gapless alignment for rat GOI. In contrast, R. norvegicus CCND1 
gene when aligned against human chromosome 11 showed at most 4.9% gapless alignment, 
which was slightly lower than the average gapless alignment for the rat GBM GOI. According to 
the results of Blast-Off, there is no direct correlation between query cover of a model organism 
or human GOI and the length of gapless alignment segments when aligned to the corresponding 
chromosome sequence.  
 
Complete GOI Alignment through NCBI BLASTn 
 
Compared to the alignments determined from Blast-Off, most sequence alignments 
between the query GOI and chromosome subject sequences were elongated through the gap 
extension and HSP overlapping. As shown in Appendix VII, the query GOI alignments with the 
highest E-values were from C. lupus and M. musculus. Across all 3 model organisms, 12 human 
GOI alignments showed E-value scores of near 0 with over 100 nucleotide alignment.  
 
Human	   Query	  
GOI	  
Comparison	  
Species	  
Gapless	  
Length	  
Final	  
Length	  
%	  Increase	  /	  	  
%	  Decrease	  
%	  Total	  
Alignment	   E-­‐value	  
EGFR	   C.	  lupus	   367	   1159	   215.8	   20.6	   0.00E+00	  
FOXO1	   C.	  lupus	   3717	   1351	   -­‐63.7	   23.5	   0.00E+00	  
HOXC13	   C.	  lupus	   145	   823	   467.6	   33.8	   0.00E+00	  
MET	   C.	  lupus	   795	   1219	   53.3	   18.2	   0.00E+00	  
MET	   M.	  musculus	   497	   1216	   144.7	   18.2	   0.00E+00	  
MYCN	   C.	  lupus	   437	   1538	   251.9	   50.5	   0.00E+00	  
MYCN	   M.	  musculus	   97	   1540	   1487.6	   50.6	   0.00E+00	  
PAX5	   M.	  musculus	   187	   1205	   544.4	   13.5	   0.00E+00	  
EGFR	   M.	  musculus	   349	   680	   94.8	   12.1	   2.00E-­‐117	  
CDK4	   C.	  lupus	   87	   615	   606.9	   30.4	   7.00E-­‐108	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PDGFRB	   M.	  musculus	   405	   334	   -­‐17.5	   5.8	   4.00E-­‐74	  
ASPSCR1	   C.	  lupus	   65	   196	   201.5	   10.5	   5.00E-­‐68	  
Table 2: Sequence length of highest E-value alignments between human GOI query sequences and associated model 
organism chromosome sequences.  
 
 
 
As shown in Table 2, with the exceptions of FOXO1 aligned to C. lupus and PDGFRB aligned to 
M. musculus, the introduction of gaps and HSP overlap resulted in a 4 fold increase in average 
sequence length.  Similar to Blast-Off, the human GOI genes MET and MYCN showed 
significant alignment when queried against the canine and mouse chromosomes. Additionally, 
when human EGFR was queried against canine and mouse chromosomes through BLASTn the 
alignments were lengthened. However when human EGFR was aligned to the R. norvegicus 
associated chromosome, there was reduction in alignment length. There were multiple human 
GOI whose alignments showed significance when queried against a single model organism, but 
were insignificant against others. Genes such as FOXO1, HOXC13, CDK4 and ASPSCR1 
showed significant alignment to C. lupus while PAX5 and PDGFRB showed significant 
alignment to M. musculus and no genes found significant alignment to R. norvegicus genome. 
However, the most complete human GBM GOI alignment found when queried against the 
associated MO chromosomes were MET, MYCN and EGFR; all 3 genes showed significant 
alignment against more than 1 model organism.  
 
Model	  
Organism	   GOI	  
Gapless	  
Length	  
Final	  
Length	  
%	   Increase	   /	   %	  
Decrease	  
Gene	  
Length	  
%	   Total	  
Alignment	   E-­‐value	  
C.	  lupus	   EGFR	   361	   1159	   221.1	   6006	   19.3	   0.00E+00	  
C.	  lupus	   IGF2	   185	   531	   187.0	   1095	   48.5	   6.00E-­‐124	  
R.	  norvegicus	   EGFR	   489	   653	   33.5	   4161	   15.7	   5.00E-­‐120	  
M.	  musculus	   AKT1	   79	   218	   175.9	   2708	   8.1	   1.00E-­‐84	  
R.	  norvegicus	   CCND1	   17	   64	   276.5	   3809	   1.7	   4.00E-­‐19	  
C.	  lupus	   PDGFRA	   79	   63	   -­‐20.3	   6234	   1.0	   1.00E-­‐06	  
Table 3: Sequence length of highest E-value alignments between model organism GOI query sequences and 
associated H. sapiens chromosome sequences.  
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Similar to the results found with human glioblastoma GOI, the introduction of gaps and HSP 
alignment increased model organism GOI alignment to associated human chromosomes by 
145.6%. Just as human PDGFRB query sequence had a reduced alignment through NCBI 
BLASTn when queried against the associated mouse chromosome, C. lupus PDGFRA query 
gene sequence also showed a sequence alignment reduction when using the BLASTn weighting 
factors. The most complete aligned model organism GOI was C. lupus IGF2 when aligned to 
human chromosome 11. Through the NCBI BLASTn algorithm, the canine GOI IGF2 had 48.5% 
alignment by introducing gaps and overlapping high-scoring pairs. Across all 3 model 
organisms, the glioblastoma GOI with the most significant alignment against the human genome 
was EGFR. Canine EGFR when aligned to human chromosome 7 showed 19.3% complete 
alignment, and rat EGFR when aligned to human chromosome 7 showed 15.7% total alignment. 
Although these alignments may be less complete than C. lupus IGF2, they show higher E-values, 
which correspond to more significant results.  
 
5. Discussion 
 
Initial BLAST Results 
 
Considering the initial results found when querying each glioblastoma GOI through 
BLAST, there were many instances where partial sequence conservation of a GOI can be found 
among the model organisms. Across all 3 model organisms the average query cover was roughly 
50%, where all HSP and extended alignments account for 50% of the entire query GOI sequence. 
It is important to note that query cover is very useful in identifying how much of a query gene 
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can be found in a genome, which may be an indicator of how similar sequences are between 2 
species. However, query cover does not take into account sequence alignment length, which is 
needed to determine total sequence conservation. Human GOI such as CHIC2, FOXO1, 
HOXC13 and PTEN showed nearly 100% query cover when aligned to a specific model 
organism, however the resulting sequences were typically small (less than 30bp). Although parts 
of a query sequence may be scattered in very small lengths across a chromosome (especially in a 
large chromosome) the genetic functionality of said alignments may be fundamentally different 
from the original gene sequence. In order to maximize the association between GOI and the 
chromosome of another organism, only the results with the highest query cover and near zero E-
values were considered in the results within section 4.  
 
Blast-Off: Gapless Sequence Conservation 
 
With the initial results determined from Blast-Off, the human gene FOXO1 aligned to 
chromosome 25 from C. lupus showed considerably higher query sequence alignment than any 
other human GOI alignment results. This may be due in part to the large number of repeating 
thymine nucleotide regions located within the human FOXO1 gene (NCBI accession number 
NM_002015.3). Due to the +1/-1 match/mismatch weights incorporated within the Blast-Off 
algorithm repeated low complexity regions would create a false sequence tolerance, in which a 
region of mismatches could be allowed where under normal circumstances it would be omitted. 
In order to determine if the FOXO1 aligned to C. lupus results should be omitted from the data 
set, a Q-test was performed. The standard Dixon’s Q-test determines outliers in a small sample 
set and its equation is as follows:  
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𝑄 =    𝑔𝑎𝑝𝑟𝑎𝑛𝑔𝑒 
In this case, gap is the difference between the outlier in question and the next closest value. And 
range is the difference between the smallest value in the data set and the largest (Efstathiou, 
2005). Using this test on FOXO1 with C. lupus and the rest of the human GOI against associated 
MO chromosomes through Blast-Off, we calculate a value of 0.784. Compared to the 95% 
confidence critical value of  .298, the human FOXO1 gene compared to C. lupus chromosome 25 
failed the Q-test and was omitted from the remaining results.  
Although the human glioblastoma GOI aligned to the 3 model organism associated 
chromosomes showed relatively overall low average gapless conservation though Blast-Off, 
these results did not take into account the number of alignments determined in a result. 
Frequently, the resulting alignment through Blast-Off would yield multiple high-scoring pair 
extensions with similar lengths, however only the longest length alignment was used in 
calculating the conservation score. Within the Blast-Off algorithm there was no overlap detection 
and therefore there may have been instances in which 2 HSP extensions overlapped and were not 
merged, which could have resulted in longer alignments and better scores.  
When looking at the 3 model organism GBM GOI sequences, there were similar low 
average gapless conservation to their related human GOI. On average, those model organism 
GOI sequences that shared a corresponding GOI to humans showed better overall alignment 
scores compared to the model organism GOI unique to that organism. Considering this 
relationship, canines and rats both shared 2 glioblastoma GOI with humans, while mice shared 
no glioblastoma GOI in common with humans. One explanation for this relationship may be 
related to the fact that mice do not spontaneously develop glioblastoma naturally and require 
induction, while canines and rats, however very rare, can develop GBM spontaneously.  
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Final Sequence Alignment through NCBI BLASTn 
 
In order to determine what the most significant alignments were across all GOI query 
sequences and the associated chromosome subject sequences, only the smallest E-value results 
were considered. Although many of the results from aligning glioblastoma query GOI to 
associated chromosome subject sequences yielded “near zero” E-value results, often times the 
difference in one “near zero” E-value to another was orders of magnitude different. In the case of 
human genes of interest, the largest magnitude difference between E-values was the result of 
ASPSCR1 aligned to C. lupus and CDK4 aligned to M. musculus. The difference in E-values 
between these two results was 53 orders of magnitude difference. Similarly, in the case of model 
organism genes of interest aligned to human chromosomes, the largest magnitude difference 
between E-values was between M. musculus AKT1 gene and R. norvegicus CCND1 gene. The 
difference between these two results was 65 orders of magnitude. There may have been 
additional differences in magnitude between E-value results as shown in Appendices VII and 
VIII, however the dramatic difference between these given results determined the cutoff as to 
which alignments were “significant” and which were not.  
When comparing the significant alignments of GOI query sequences to their associated 
chromosome’s subject sequences through BLASTn, there were instances where sequence lengths 
decreased from the results obtained though Blast-Off. In the case of human genes of interest, 
there were only 2 resulting alignments whose sequence lengths decreased, and in the case of 
model organism genes of interest there was only 1 alignment whose sequence length decreased. 
When human GOI FOXO1 gene was aligned to C. lupus chromosome 25 its resulting alignment 
decreased by 63.7%, and when PDGFRB was aligned to M. musculus chromosome 18 its 
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resulting alignment decreased by 17.5%. Additionally when C. lupus gene PDGFRA was aligned 
to the human chromosome 4, the resulting sequence alignment decreased by 20.3%. The 
sequence reduction found from FOXO1, PDGFRB and PDGFRA was most likely due to 
alignment of low-complexity regions, which were omitted from the NCBI BLASTn results. 
Although these results may have seen a reduction from the NCBI BLASTn algorithm, the stricter 
match/mismatch/gap scoring parameters should have resulted in a far more accurate alignment of 
the query sequences against the subject chromosome sequences.  
 
6. Conclusions 
 
Throughout this study, many genes of interest were identified in humans, canines, rats 
and mice; some identified genes of interest were shared between organisms while others were 
unique to that species. As shown with the initial BLAST searches across the compressed 
GenBank database, most genes of interest shared partial conserved sequence regions between 
genomes.  
Across all 3 model organisms tested the average query cover of any human gene of 
interest was roughly 50%, which means that on average 50% of each human gene of interest was 
conserved within fragments across a given model organism chromosome. Although on average 
50% of each human GOI was conserved in fragments across an associated model organism 
chromosome, most of the fragments were relatively small sequences aligned from the query GOI 
sequence. When tested through the Blast-Off program for the largest gapless alignment 
sequences, the only 3 human GOI sequences that showed larger than 10% sequence alignment 
were CHIC2, MET, and MYCN, all of which were aligned to C. lupus. However, when using a 
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more robust scoring parameters and allowing for HSP overlap such as the NCBI BLASTn 
algorithm, there were multiple human GOI alignments that were between 10-60% overall 
sequence conservation. The most highly conserved human GBM genes of interest found were 
EGFR, MET and MYCN. All 3 genes showed more than 15% conserved sequence across more 
than 1 model organism.  
Across the glioblastoma genes of interest with the most significant copy number 
alterations such as MET, EGFR and PTEN, the conservation of sequence varied. For the genes 
MET and EGFR, which were identified as copy-number amplification events, showed higher 
than average sequence conservation across all 3 model organisms. MET and EGFR were both 
identified as oncogenes linked to glioblastoma, therefore the higher conservation of these gene 
sequences within each model organism may result in a higher chance of the oncogenetic 
properties found in human GBM being conserved within the model organism.  However, in both 
cases, when the genes of interest were aligned to R. norvegicus the resulting sequence 
conservation was lower than average. The low sequence conservation identified in R. norvegicus 
was not unique to the genes identified as significant copy-number alteration GOI, R. norvegicus 
consistently showed the overall lowest sequence conservation of all 3 model organisms, which 
may just be a result of genetic difference between species. In contrast, the PTEN gene region, 
which was found to be the most significant copy-number deletion event associated to H. sapiens 
glioblastoma development, showed lower than average sequence conservation between all 3 
model organisms. Just as the higher conservation of oncogenes MET and EGFR may increase 
the chance that oncogenetic properties could be conserved within the model organism, the 
reduced conservation of the tumor suppressor gene PTEN may also result in a reduction of tumor 
suppressor properties found in each model organism.  
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In the case of model organism genes of interest linked to human chromosomes, those 
genes of interest that were linked to both model organisms and humans, such as CCND1, 
PDGFR and EGFR, showed higher average query coverage and higher average gapless sequence 
conservation than those GOI unique to their species. Additionally, when the query GOI 
sequences were tested through NCBI BLASTn, where gaps and HSP extensions were calculated, 
CCND1, PDGFR and EGFR showed some of the highest sequence conservation of all model 
organisms GBM gene of interest sequences.  
Compared to other studies focused on phenotypic expression and genetic manipulation of 
glioblastoma genes of interest such as MET and EGFR, this study was unique in comparing the 
overall sequence conservation of GBM GOI sequences between humans and the model 
organisms used in studying glioblastoma. Although many other model organisms have been used 
in the study of glial tumor cells and their effect on the body, our knowledge and understanding of 
the genetic influences linked to GBM are still very limited. One major advantage of this study 
was the ability to use full model organisms and human chromosome sequences and GOI query 
sequences, which were available publicly and for free through the NCBI database. Future work 
on the identification of conserved sequence regions between human glioblastoma GOI and 
associated model organism chromosomes should include identification of functional regions 
within the conserved regions. Due to the limitations of the BLAST algorithm there is no way to 
determine which regions are exons and which are introns, therefore many of these conserved 
regions identified in Blast-Off and BLASTn may have no impact on the development of 
glioblastoma in humans, canines or rats. However using the BLAST algorithm over other 
heuristic algorithms allows the user a means of rapidly identifying a conserved region between 
sequences, which can then be applied to a more intelligent algorithm to detect functional regions.  
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8. Appendices 
 
 
Appendix I - NCBI Blast Results for H. sapiens GOI 
 
 
Gene Chromosome  Related Organism Accession No. Chromosome Query Cover E-value 
PTEN 10q23.3 M. musculus NM_008960.2 19 0.96 0 
PTEN 10q23.3 C. lupus NM_001003192.1 26 0.24 0 
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PTEN 10q23.3 R. norvegicus NM_031606.1 1 0.21 0 
MET 7q31 M. musculus NM_008591.2 6 0.62 0 
MET 7q31 C. lupus NM_001002963.1 14 0.65 0 
MET 7q31 R. norvegicus NM_031517.2 4 0.61 0 
NOTCH
1 9q34.3 M. musculus NM_008714.3 2 0.85 0 
NOTCH
1 9q34.3 C. lupus XM_005625433.1 9 0.88 0 
NOTCH
1 9q34.3 R. norvegicus NM_001105721.1 3 0.85 0 
PAX5 9p13 M. musculus NM_008782.2 4 0.13 0 
PAX5 9p13 C. lupus XM_005626822.1 11 0.14 0 
PAX5 9p13 R. norvegicus NM_001109261.1 5 0.13 0 
RECQL
4 8q24.3 M. musculus NM_058214.3 15 0.24 4.00E-156 
RECQL
4 8q24.3 C. lupus XM_005628318.1 13 0.51 0 
RECQL
4 8q24.3 R. norvegicus NM_001130494.1 7 0.31 0 
CRTC1 19p13.11 M. musculus NM_001004062.2 8 0.29 0 
CRTC1 19p13.11 C. lupus XM_003432890.2 20 0.37 0 
CRTC1 19p13.11 R. norvegicus NM_001047115.1 16 0.27 0 
STK11 19p13.3 M. musculus NM_011492.3 10 0.39 0 
STK11 19p13.3 C. lupus XM_005633151.1 20 0.42 0 
STK11 19p13.3 R. norvegicus NM_001108069.1 7 0.39 0 
MYCN 2p24.3 M. musculus NM_008709.3 12 0.81 0 
MYCN 2p24.3 C. lupus XM_005630146.1 17 0.49 0 
MYCN 2p24.3 R. norvegicus NM_001013096.1 6 0.81 0 
CHIC2 4q11 M. musculus NM_028850.4 5 0.97 0 
CHIC2 4q11 C. lupus XM_005628193.1 13 0.58 0 
CHIC2 4q11 R. norvegicus NM_001105736.2 14 0.7 0 
EGFR 7p12 M. musculus NM_207655.2 11 0.65 0 
EGFR 7p12 C. lupus XM_533073.4 18 0.63 0 
EGFR 7p12 R. norvegicus NM_031507.1 14 0.66 0 
FOXO1 13q14.1 M. musculus NM_019739.3 3 0.68 0 
FOXO1 13q14.1 C. lupus XM_534487.4 25 0.95 0 
FOXO1 13q14.1 R. norvegicus NM_001191846.2 2 0.44 0 
CDK4 12q14 M. musculus NM_009870.3 10 0.54 0 
CDK4 12q14 C. lupus XM_844780.3 10 0.71 0 
CDK4 12q14 R. norvegicus NM_053593.2 7 0.54 0 
CCND1 11q13 M. musculus NM_007631.2 7 0.4 0 
CCND1 11q13 C. lupus NM_001005757.1 18 0.29 0 
CCND1 11q13 R. norvegicus NM_171992.4 1 0.39 0 
ASPSC
R! 17q25.3 M. musculus NM_026877.2 11 0.76 0 
ASPSC
R! 17q25.3 C. lupus XM_533134.4 9 0.73 0 
ASPSC
R! 17q25.3 R. norvegicus XM_002724585.4 10 0.75 0 
FANCA 16q24.3 M. musculus N/A N/A    
FANCA 16q24.3 C. lupus N/A N/A    
FANCA 16q24.3 R. norvegicus NM_001108455.1 19 0.68 0 
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PDGFR
B 5q33.1 M. musculus NM_001146268.1 18 0.56 0 
PDGFR
B 5q33.1 C. lupus NM_001003382.1 4 0.67 0 
PDGFR
B 5q33.1 R. norvegicus NM_031525.1 18 0.57 0 
FGFR3 4p16.3 M. musculus NM_008010.5 5 0.76 0 
FGFR3 4p16.3 C. lupus XM_005618527.1 3 0.61 0 
FGFR3 4p16.3 R. norvegicus NM_053429.1 14 0.56 0 
HOXC1
3 12q13.3 M. musculus NM_010464.2 15 0.58 0 
HOXC1
3 12q13.3 C. lupus XM_851714.3 27 0.97 0 
HOXC1
3 12q13.3 R. norvegicus XM_235695.7 7 0.44 0 
 
 
Appendix II - NCBI Blast Results for M. musculus GOI 
 
 
Gene Chromosome Related Organism Accession No. Chromosome Query Cover E-value 
HRAS 7 H. sapiens N/A N/A 0 0 
AKT1 12 H. sapiens NM_005163.2 14q32.32 0.65 0 
NF1 11 H. sapiens NM_001042492.2 17q11.2 0.86 0 
TRP53 11 H. sapiens NM_000546.5 17p13.1 0.65 0 
 
 
 
Appendix III – NCBI Blast Results for R. norvegicus GOI 
 
 
Gene Chromosome  Related Organism Accession No. Chromosome Query Cover E-value 
IGF1 7 H. sapiens NM_001111283.1 12q23.2 0.96 0 
EGFR 14 H. sapiens NM_005228.3 7p12 0.97 0 
CCND1 1 H. sapiens NM_053056.2 11q13 0.68 0 
NGF 2 H. sapiens NM_002506.2 1p13.1 0.97 0 
 
 
Appendix IV – NCBI Blast Results for C. lupus GOI 
 
 
Gene Chromosome Related Organism Accession No. Chromosome  Query Cover E-value 
TP53 5 H. sapiens NM_000546.5 17 0.79 0 
EGFR 18 H. sapiens NM_005228.3 7p12 0.77 0 
PDGFRA 13 H. sapiens NM_006206.4 4q12 0.97 0 
IGF2 18 H. sapiens NM_000612.5 11p15.5 0.83 0 
 
 
Appendix V – Blast-Off Utility Results for H. sapiens 
 
 
Page 61	  
Query Gene Comparison Species MO Chromosome Number Max Length % Alignment 
ASPSCR1 C. lupus 9 65 0.035 
ASPSCR1 M. musculus 11 129 0.069 
ASPSCR1 R. norvegicus 10 39 0.021 
CCND1 C. lupus 18 127 0.03 
CCND1 M. musculus 7 135 0.031 
CCND1 R. norvegicus 1 17 0.004 
CDK4 C. lupus 10 87 0.043 
CDK4 M. musculus 10 99 0.049 
CDK4 R. norvegicus 7 75 0.037 
CHIC2 C. lupus 13 125 0.106 
CHIC2 M. musculus 5 103 0.087 
CHIC2 R. norvegicus 14 75 0.064 
CRTC1 C. lupus 20 99 0.014 
CRTC1 M. musculus 8 207 0.03 
CRTC1 R. norvegicus 16 149 0.021 
EGFR C. lupus 18 367 0.065 
EGFR M. musculus 11 349 0.062 
EGFR R. norvegicus 14 35 0.006 
FANCA C. lupus N/A 0 0 
FANCA M. musculus N/A 0 0 
FANCA R. norvegicus 19 57 0.01 
FGFR3 C. lupus 3 127 0.03 
FGFR3 M. musculus 5 155 0.036 
FGFR3 R. norvegicus 14 125 0.029 
FOXO1 C. lupus 25 3717 0.648 
FOXO1 M. musculus 3 77 0.013 
FOXO1 R. norvegicus 2 51 0.009 
HOXC13 C. lupus 27 145 0.06 
HOXC13 M. musculus 15 127 0.052 
HOXC13 R. norvegicus 7 119 0.049 
MET C. lupus 14 795 0.119 
MET M. musculus 6 497 0.074 
MET R. norvegicus 4 105 0.016 
MYCN C. lupus 17 437 0.143 
MYCN M. musculus 12 97 0.032 
MYCN R. norvegicus 6 99 0.033 
NOTCH1 C. lupus 9 83 0.009 
NOTCH1 M. musculus 2 63 0.007 
NOTCH1 R. norvegicus 3 33 0.004 
PAX5 C. lupus 11 147 0.017 
PAX5 M. musculus 4 187 0.021 
PAX5 R. norvegicus 5 79 0.009 
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PDGFRB C. lupus 4 77 0.013 
PDGFRB M. musculus 18 405 0.071 
PDGFRB R. norvegicus 18 37 0.006 
PTEN C. lupus 26 135 0.024 
PTEN M. musculus 19 97 0.017 
PTEN R. norvegicus 1 105 0.019 
RECQL4 C. lupus 13 83 0.022 
RECQL4 M. musculus 15 77 0.02 
RECQL4 R. norvegicus 7 75 0.02 
STK11 C. lupus 20 95 0.029 
STK11 M. musculus 10 101 0.031 
STK11 R. norvegicus 7 87 0.026 
 
 
 
 
Appendix VI – Blast-Off Utility Results for Model Organisms 
 
 
Model Organism Query Gene DB Chromosome Max Length % Alignment 
M. musculus AKT1 14q32.32 79 0.029 
M. musculus NF1 17q11.2 51 0.004 
M. musculus TRP53 17p13.1 67 0.038 
R. norvegicus IGF1 12q23.2 103 0.065 
R. norvegicus EGFR 7p12 489 0.118 
R. norvegicus CCND1 11q13 187 0.049 
R. norvegicus NGF 1p13.1 15 0.014 
C. lupus TP53 17 31 0.026 
C. lupus EGFR 7p12 361 0.06 
C. lupus PDGFRA 4q12 79 0.013 
C. lupus IGF2 11p15.5 185 0.169 
 
 
Appendix VII – NCBI Blast Results for Human GOI to Associated MO Chromosomes 
 
 
Query Gene Comparison Species 
Sequence 
Length Identities Gaps 
Gene 
Length % Alignment E-value 
EGFR C. lupus 1159 852 89 5616 20.64 0.00E+00 
FOXO1 C. lupus 1351 1236 0 5738 23.54 0.00E+00 
HOXC13 C. lupus 823 762 20 2435 33.80 0.00E+00 
MET C. lupus 1219 1080 3 6695 18.21 0.00E+00 
MET M. musculus 1216 1038 3 6695 18.16 0.00E+00 
MYCN C. lupus 1538 1377 53 3046 50.49 0.00E+00 
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MYCN M. musculus 1540 1331 44 3046 50.56 0.00E+00 
PAX5 M. musculus 1205 963 70 8908 13.53 0.00E+00 
EGFR M. musculus 680 510 30 5616 12.11 2.00E-117 
CDK4 C. lupus 615 461 68 2020 30.45 7.00E-108 
PDGFRB M. musculus 334 264 9 5718 5.84 4.00E-74 
ASPSCR1 C. lupus 196 176 3 1858 10.55 5.00E-68 
CDK4 M. musculus 66 58 1 2020 3.27 5.00E-15 
CDK4 R. norvegicus 53 48 1 2020 2.62 2.00E-11 
CRTC1 M. musculus 79 62 1 6961 1.13 2.00E-08 
MET R. norvegicus 67 54 4 6695 1.00 2.00E-07 
CRTC1 R. norvegicus 41 36 0 6961 0.59 2.00E-05 
MYCN R. norvegicus 39 34 0 3046 1.28 2.00E-05 
PDGFRB R. norvegicus 68 52 0 5718 1.19 2.00E-05 
PTEN C. lupus 53 43 0 5572 0.95 4.00E-05 
NOTCH1 M. musculus 81 60 0 9309 0.87 5.00E-05 
PDGFRB C. lupus 56 44 0 5718 0.98 2.00E-04 
RECQL4 C. lupus 29 27 1 3840 0.76 4.00E-03 
CHIC2 C. lupus 36 31 0 1178 3.06 5.00E-03 
CCND1 C. lupus 55 43 1 4304 1.28 1.50E-02 
PTEN M. musculus 45 36 0 5572 0.81 1.60E-02 
NOTCH1 R. norvegicus 27 25 1 9309 0.29 1.70E-02 
FGFR3 C. lupus 42 36 2 4304 0.98 1.90E-02 
CHIC2 M. musculus 32 28 3 1178 2.72 2.30E-02 
STK11 M. musculus 42 34 3 3286 1.28 2.30E-02 
FANCA R. norvegicus 37 31 0 5460 0.68 3.40E-02 
FOXO1 M. musculus 28 26 1 5738 0.49 3.40E-02 
CCND1 M. musculus 39 33 2 4304 0.91 7.20E-02 
CRTC1 C. lupus 27 25 0 6961 0.39 8.20E-02 
HOXC13 M. musculus 35 29 0 2435 1.44 8.20E-02 
FGFR3 M. musculus 40 33 3 4304 0.93 8.40E-02 
NOTCH1 C. lupus 31 27 0 9309 0.33 1.10E-01 
PAX5 C. lupus 21 21 0 8908 0.24 1.30E-01 
STK11 C. lupus 33 29 1 3286 1.00 1.30E-01 
ASPSCR1 R. norvegicus 18 18 0 1858 0.97 1.70E-01 
STK11 R. norvegicus 30 26 0 3286 0.91 1.90E-01 
ASPSCR1 M. musculus 20 20 0 1858 1.08 3.30E-01 
PAX5 R. norvegicus 21 19 0 8908 0.24 4.80E-01 
HOXC13 R. norvegicus 24 22 0 2435 0.99 4.90E-01 
PTEN R. norvegicus 28 25 0 5572 0.50 5.60E-01 
RECQL4 R. norvegicus 33 28 2 3840 0.86 7.80E-01 
FOXO1 R. norvegicus 19 18 0 5738 0.33 1.10E+00 
RECQL4 M. musculus 26 23 0 3840 0.68 1.60E+00 
CHIC2 R. norvegicus 17 16 0 1178 1.44 3.10E+00 
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EGFR R. norvegicus 15 15 0 5616 0.27 4.30E+00 
CCND1 R. norvegicus 15 14 0 4304 0.35 7.10E+00 
 
 
Appendix VIII – NCBI Blast Results for MO GOI to Associated Human Chromosomes 
 
 
Query Gene GOI Species Sequence Length Identities Gaps Gene Length % Alignment E-value 
EGFR C. lupus 1159 852 89 6006 19.30 0.00E+00 
IGF2 C. lupus 531 425 20 1095 48.49 6.00E-124 
EGFR R. norvegicus 653 493 44 4161 15.69 5.00E-120 
AKT1 M. musculus 218 210 0 2708 8.05 1.00E-84 
CCND1 R. norvegicus 64 60 0 3809 1.68 4.00E-19 
PDGFRA C. lupus 63 50 0 6234 1.01 1.00E-06 
NGF R. norvegicus 18 18 0 1075 1.67 1.90E-02 
TP53 C. lupus 21 20 0 1174 1.79 3.10E-02 
TRP53 M. musculus 16 16 0 1781 0.90 5.80E-01 
IGF1 R. norvegicus 18 18 0 1582 1.14 7.60E-01 
NF1 M. musculus 20 19 0 11847 0.17 1.10E+00 
 
 
Appendix IX – Final Alignments for GBM GOI to Associated Chromosomes 
 
 
Organism: C. lupus   
Query Gene: EGFR   
Subject 
Organism: H. sapiens   
Subject 
Chromosome: 7     
Sequence Starting Position Sequence Ending Position 
Query 3184 GAATACATAAACCAGTCTGTTCCCAAAAGGCCTGCGGGTTCTGTCCAGAATCCCGTCTAT 3243 
Sbjct 55195255 GAATACATAAACCAGTCCGTTCCCAAAAGGCCCGCTGGCTCTGTGCAGAATCCTGTCTAT 
5519531
4 
Query 3244 CACAATCAGCCTCTAAATCCAGCTCCTGCCAGAGACCCTCACTACCAAAATCCCCACAGC 3303 
Sbjct 55195315 CACAATCAGCCTCTGAACCCCGCGCCCAGCAGAGACCCACACTACCAGGACCCCCACAGC 
5519537
4 
Query 3304 AACGCAGTGGACAACCCTGAGTATCTCAACAC---CCACCCCACCTGCGTCAACAGTGTC 3360 
Sbjct 55195375 ACTGCAGTGGGCAACCCCGAGTATCTCAACACTGTCCAGCCCACCTGTGTCAACAGCACA 
5519543
4 
Query 3361 CTCGACAGGCCCAGCCTCTGGACCCAGGAGGCCAACCACCAAATCAGCCTGGACAACCCT 3420 
Sbjct 55195435 TTCGACAGCCCTGCCCACTGGGCCCAGAAAGGCAGCCACCAAATTAGCCTGGACAACCCT 
5519549
4 
Query 3421 GACTACCAGCAGGACTTCTTTCCCAAGGAAGCCAAGTCCAATGGCATTTTTAAGGGCCCT 3480 
Sbjct 55195495 GACTACCAGCAGGACTTCTTTCCCAAGGAAGCCAAGCCAAATGGCATCTTTAAGGGCTCC 
5519555
4 
Query 3481 GCAGCTGAAAATGCAGACTACCTGAGGGTAGCGCCACCAAGCAGTGAGTTTATTGGAGCG 3540 
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Sbjct 55195555 ACAGCTGAAAATGCAGAATACCTAAGGGTCGCGCCACAAAGCAGTGAATTTATTGGAGCA 
5519561
4 
Query 3541 TGACCACGGAGGATAGCCTTGGCCATAAGAGTCTCAGA-TGTTTCAGCCCCCTGGGACCC 3599 
Sbjct 55195615 TGACCACGGAGGATAGTATGAGCCCTAAAAATC-CAGACTCTTTC-GATACCCAGGACCA 
5519567
2 
Query 3600 AGTCTTGGCAGCTGCTCCAGTGCTGATA-ACATGCCCACATTAACTCTTGGACCTGTTGA 3658 
Sbjct 55195673 AGCCACAGCAGGTCCTCCA-TCCCAACAGCCATGCCCGCATTAGCTCTTAGACCCACAGA 
5519573
1 
Query 3659 CTGGTTTGGCCCTATTTGCTCCGATGGACTCATCTTTCACCCAGGATGTGCCCGCTACGT 3718 
Sbjct 55195732 CTGGTTTTGCAACGTTTACACC----GACT--------AGCCAGGAAGTAC--------- 55195770 
Query 3719 GGATGTACTTTGGGAAGAGTTACTGGGACATTCCATTCCTTTGTCTTCAAACTGTGAGGC 3778 
Sbjct 55195771 --TTCCACCTCGGGCACATTT--TGGGAAGTTGCATTCCTTTGTCTTCAAACTGTGAAGC 
5519582
6 
Query 3779 CTCCGCAAAAAGGCATCCAGCAAGAATATTGTCTATTTGGGCAGAAGTTCACCTTCCGAT 3838 
Sbjct 55195827 ATTTACAGAAACGCATCCAGCAAGAATATTGTCCCTTTGAGCAGAAATTTATCTTTCAAA 
5519588
6 
Query 3839 GAGGTATATTTGATTTaaaaaaaaaaaaaaaaCTGTAAAAGGAATTTTATTGCTTGGGGA 3898 
Sbjct 55195887 GAGGTATATTTGA---AAAAAAAAAAAAGTATATGT--GAGGATTTTTATTGATTGGGGA 
5519594
1 
Query 3899 CCCTTGAGGCAATTTTAATTGTCATCATTGA-TTTTATTTCTCGTGGGCTTTTCCAATGG 3957 
Sbjct 55195942 TCTTGGAG---TTTTTCATTGTCGCTATTGATTTTTACTTC-AATGGGCTCTTCCAACAA 
5519599
7 
Query 3958 GGAAGAAGCTTGCTCATAGCACTTGCTGCACTGAGTTGATCCAGGCTCAACTGTGACCAA 4017 
Sbjct 55195998 GGAAGAAGCTTGCTGGTAGCACTTGCTACCCTGAGTTCATCCAGGCCCAACTGTGAGCAA 
5519605
7 
Query 4018 GAAGCAAGGGTCA-GAGTCTTCCAGCTAACCTTTGATTCCACTGACTCTGCTTCAAGATT 4076 
Sbjct 55196058 GGAGCACAAGCCACAAGTCTTCCAGAGGATGCTTGATTCCAGTGGTTCTGCTTCAAG--G 
5519611
5 
Query 4077 CTCCCACTGCAAGACAATTaaaaaaacaaaaaacaaaaaaacaaaaaaaaaaaaaGAAAC 4136 
Sbjct 55196116 CTTCCACTGCAAAACACT----------------------------------AAAGATCC 55196141 
Query 4137 AGAACTCTAGGAGTACTCAGAGTCCTAAGCAGGACGGATTGATACTGTAGCAAATCATAG 4196 
Sbjct 55196142 
A-------
AGAAGGCCTTCATGGCCCCAGCAGGCCGGATCGGTACTGTATCAAGTCATG
G 
5519619
4 
Query 4197 CAGGTACAAGAGGATAAGCCACTTTGAACCCTTCCTGATTGGAGAAGAAATGCAGGCG-T 4255 
Sbjct 55196195 CAGGTACAGTAGGATAAGCCACTCTG-TCCCTTCCTGGGCAAAGAAGAAACGGAGGGGAT 
5519625
3 
Query 4256 AGACTTCTTCTTCAGACTTCTTTTTATATAAATTTCTTCATGGTACTTACTCTCTATCGG 4315 
Sbjct 55196254 GGAATTCTTCCTTAGACTTACTTTTGTAAAAATGTCCCCACGGTACTTACTCCCCACTGA 
5519631
3 
Query 4316 TCGACCAGTGTTTTCTAGT 4334 
Sbjct 55196314 TGGACCAGTGGTTTCCAGT 55196332 
 
 
 
Organism: C. lupus   
Query Gene: IGF2   
Subject 
Organism: H. sapiens   
Subject 
Chromosome: 11     
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Sequence Starting Position Sequence Ending Position 
Query 471 
GGACAACTTCCCCAGATACCCCGTGGGCAAGTTCTTCCAATACGACACCTG
GAAGCAGTC 530 
Sbjct 2073224 
GGACAACTTCCCCAGATACCCCGTGGGCAAGTTCTTCCAATATGACACCTG
GAAGCAGTC 2073165 
Query 531 
CGCCCAACGCCTGCGCAGAGGTCTGCCTGCCCTCCTGCGCGCCCGGCGGGG
TCGCATGCT 590 
Sbjct 2073164 
CACCCAGCGCCTGCGCAGGGGCCTGCCTGCCCTCCTGCGTGCCCGCCGGGG
TCACGTGCT 2073105 
Query 591 
CGCCAAGGAGCTCGAGGCGTTCAGAGAGGCCAAGCGTCACCGTCCGCTGAT
CGCCCTGCC 650 
Sbjct 2073104 
CGCCAAGGAGCTCGAGGCGTTCAGGGAGGCCAAACGTCACCGTCCCCTGAT
TGCTCTACC 2073045 
Query 651 
CACCCACGACCCCGCCACCCACGGGGGCGCCTCTCCAGAGGCATCCGGCAA
TCAGAAGTG 710 
Sbjct 2073044 
CACCCAAGACCCCG---
CCCACGGGGGCGCCCCCCCAGAGATGGCCAGCAATCGGAAGTG 2072988 
Query 711 
AGCCAAAATGTCGCGTAATTCTGCAAGACGGCACCGTCCACCTCGTGC--
CCTCCTCTTG 768 
Sbjct 2072987 
AGCAAAACTGCCGC--AAGTCTGCAGCCCGGCGCC-ACCA--
TCCTGCAGCCTCCTCCTG 2072933 
Query 769 
ACCAGGGGCCATTCCATCGGGTCCCGCCTCTAACATCTCTCGAGGTCGCGTT
CCCTCTGC 828 
Sbjct 2072932 
ACCACGGACGTTTCCATCAGGTTCCATCCCGAAAATCTCTCG-
GTTCCACGTCCCCCTG- 2072875 
Query 829 GGGCTcccccacccccagcccccatgccccaacctccccaTGTCAGGCTCTTCTCTCCTT 888 
Sbjct 2072874 
GGGCTTCTCCTGACCCAGTCCCCGTGCCCC-GCCTCCCCGAAACAGG--
CTACTCTCCTC 2072818 
Query 889 
GGCCCTCTCCATCAGGCTGAGGAGATCCTAGTAACACCTCTAAAAATGTAC
AAACTCAAT 948 
Sbjct 2072817 
GGCCCCCTCCATCGGGCTGAGGA-
AGCACAGCAGCATCTTCAAACATGTACAAAATCGAT 2072759 
Query 949 TGGCTTTCATAACCCCCCAAAATTAcc--ccccccAAATTATCCCAAATTA 997 
Sbjct 2072758 TGGCTTTAAACACCCTTCACA--TACCCTCCCCCCAAATTATCCCCAATTA 2072710 
 
 
Organism: C. lupus   
Query Gene: PDGFRA   
Subject 
Organism: H. sapiens   
Subject 
Chromosome: 4     
Sequence Starting Position Sequence Ending Position 
Query 2782 
CTGGTCCTACGGCATCCTGCTCTGGGAGATCTTTTCCCTTGGCGGCACACCC
TACCCTGG 2841 
Sbjct 1796546 
CTGGTCCTTTGGGGTCCTGCTCTGGGAGATCTTCACGCTGGGGGGCTCCCCG
TACCCCGG 1796605 
Query 2842 CAT 2844 
Sbjct 1796606 CAT 1796608 
 
 
Organism: C. lupus   
Query Gene: TP53   
Subject 
Organism: H. sapiens   
Subject 
Chromosome: 17     
Sequence Starting Position Sequence Ending Position 
Query 729 CCATCCTCACTATCATCACCC 749 
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Sbjct 284013 CCATCATCACTATCATCACCC 284033 
    
 
Organism: H. sapiens   
Query Gene: ASPSCR1   
Subject 
Organism: C. lupus   
Subject 
Chromosome: 9     
Sequence Starting Position Sequence Ending Position 
Query 9 CCCGCCCCCTGGCCGCGTGGCTGCGCGTCCTGGCTGTTGCCGATAAAGTTGTTTGACGCC 68 
Sbjct 331153 CCCGCCCCGCCCCCGCGTGGCTCTGCGTCCCGGCTGTTAGCGAGAAAGTGGTTTGACGCC 331094 
Query 69 
G-GCC--
CGGCGGCGGGTCACGTGAGCGGAAAATGGCGGCCCCGGCAGGCGGCGGAGG
CT 
125 
Sbjct 331093 GAGCCGGCGGCGGCGGGTCACGTGAGCGGAAGATGGCGGCCCCGGGTGGCGGCGGGGGCT 331034 
Query 126 CCGCGGTGTCGGTGCTGGCCCCGAACGGCCGGCGCCACACGGTGAAGGTGACGCCGAGCA 185 
Sbjct 331033 CCGCGGTGTCGGTGCTGGCCCCGAACGGGCGGCGCCACACGGTGAAGGTGACGCCGAGCA 330974 
Query 186 CCGTGCTGCTTCAGGT 201 
Sbjct 330973 CCGTGCTGCTGCAGGT 330958 
 
 
Organism: H. sapiens   
Query Gene: ASPSCR1   
Subject 
Organism: M. musculus   
Subject 
Chromosome: 11     
Sequence Starting Position Sequence Ending Position 
Query 1511 CTGGAGCCTGGCCTGCTGGA 1530 
Sbjct 24318261 CTGGAGCCTGGCCTGCTGGA 24318242 
 
 
Organism: H. sapiens   
Query Gene: ASPSCR1   
Subject 
Organism: R. norvegicus   
Subject 
Chromosome: 10     
Sequence Starting Position Sequence Ending Position 
Query 231 TCAACCCCTGTGAATATG 248 
Sbjct 63186 TCAACCCCTGTGAATATG 63203 
 
 
Organism: H. sapiens   
Query Gene: CCND1   
Subject 
Organism: C. lupus   
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Subject 
Chromosome: 18     
Sequence Starting Position Sequence Ending Position 
Query 3692 TTTTGGGTATGTTTAATCTGTTATGTACTAGTGTTCTGTTTGTTATTGTTTTGTT 3746 
Sbjct 12814870 TTTTGGATATTTCTTCTCTGTTAAGACATGGTTTTCTGTTTGTT-TTGTTTTGTT 12814817 
 
 
Organism: H. sapiens   
Query Gene: CCND1   
Subject 
Organism: M. musculus   
Subject 
Chromosome: 7     
Sequence Starting Position Sequence Ending Position 
Query 3692 TTTTGGGTATGTTTAATCTGTTATGTACTAGTGTTCTGTTTGTTATTGTTTTGTT 3746 
Sbjct 12814870 TTTTGGATATTTCTTCTCTGTTAAGACATGGTTTTCTGTTTGTT-TTGTTTTGTT 12814817 
 
 
Organism: H. sapiens   
Query Gene: CCND1   
Subject Organism: R. norvegicus   
Subject 
Chromosome: 1     
Sequence Starting Position Sequence Ending Position 
Query 1414 TTTTTATATTAATGT 1428 
Sbjct 865 TTTTTATATTAAAGT 851 
 
 
Organism: H. sapiens   
Query Gene: CDK4   
Subject 
Organism: C. lupus   
Subject 
Chromosome: 10     
Sequence Starting Position Sequence Ending Position 
Query 1111 GGAAATGCTGACTTTTAACCCACACAAGCGAATCTCTGCCTTTCGAGCTCTGCAGCACTC 1170 
Sbjct 1813177 GGAGATGCTGACTTTTAACCCACACAAGCGAATCTCTGCCTTCCGAGCCCTGCAGCACTC 1813118 
Query 1171 TTATCTACATAAGGATGAAGGTAATCCGGAGTGAGCAATGGAGTGGCTGCCATGGAAGGA 1230 
Sbjct 1813117 TTATCTACAAAAGGCAGAAGGTAACCCAGAGTGAGCAGTGGAATGGCTGCAACGGTAGCA 1813058 
Query 1231 AGAA-----AAGCTGCCATTTCCCTTC---TGGACACT------GAGAG----------- 1265 
Sbjct 1813057 AGAGGAGAGAAGCTGTCTTTTCTCTTCCTTTGAACACTTGAGTGGAGAGCTCCCCAAACT 1812998 
Query 1266 
-----
GGCAATCTTTGCCTTTATCTCTGAGGCTATGGAGGGTCCTCCTCCATCTTTCTA
C 
1320 
Sbjct 1812997 AAGAAGGCAGTCTTGACCTTCATCTCTGAGGCTGTGGAAACAACTCC--CA-CTTTTTAC 1812941 
Query 1321 AGAGATTACTTTGCTGCCTTAATGACATTCCCCTCCCACCTCTCCTTTTGAGGCTTCTCC 1380 
Page 69	  
Sbjct 1812940 AGAGAATATTTTGCTGCCTTAATGACATTCCCTTTCCACCTCTCCTTTTGAGGCTTATCC 1812881 
Query 1381 TT----------CTCCTTCCCATTTCTCTACACTAA-GGGGTATGTTCCCTCTTGTCCCT 1429 
Sbjct 1812880 TTCTCCTGCCCCCTCCTCCCCATTTTCATACACCAAGGGGGTATGTCCCTTGTTCTCCCC 1812821 
Query 1430 TTCCCTACCTTTATATTTGGGGTCCTTTTTTATACAGGAAAAACAAAACAAAGAAATAAT 1489 
Sbjct 1812820 TT-TCTATCTTGATATT--GGGATCTTTTTTATACAGGAAAAACAAAACAAAGAAAT-AT 1812765 
Query 1490 GGTCttttttttttttttAATGTTTCTTCCTCTGTTTGGCTTTGCCATTGTGCGATTTGG 1549 
Sbjct 1812764 GGTCTTTTTTTTTTTGTT--TGTTTCTTCCTCTGATGGGTATTGCCATTTAGGGACTTGG 1812707 
Query 1550 AAAAACCACTTGGAAGAAGGGACTTTCCTGCAAAACCTTAAAGACTGGTTAAATTACAGG 1609 
Sbjct 1812706 AAAAATCA-TTCGTAGAA--------TCTG-AAAACATT-----CTCCCTAGGTCCTAGG 1812662 
Query 1610 GCCTAGGAAGTC-AGTGGAGCCCCTTGACTGACAA-AGCTTAGAAAGGAACTGAAATTGC 1667 
Sbjct 1812661 GCCTATGTAGGCAATTGGAGCCCCTCAACTGGCAAGAGAAGA-AAAGGCACTTAAGTTGC 1812603 
Query 1668 TTCTTTGAATATGGA 1682 
Sbjct 1812602 TTCTTTGAATACGGA 1812588 
 
 
Organism: H. sapiens   
Query Gene: CDK4   
Subject 
Organism: M. musculus   
Subject 
Chromosome: 10     
Sequence Starting Position Sequence Ending Position 
Query 1817 AAATTAGTCAGGCGTGGTGGTGCACACCTGTAATCCCAGCTACTTGGGAGACTGAGGCAG 1876 
Sbjct 1408156 AAAGTAGCCAGGCGTGGTGGCGCACACCTTTAATCCCAGC-ACTTGGGAGGCAGAGGCAG 1408214 
Query 1877 GAGGAT 1882 
Sbjct 1408215 GCGGAT 1408220 
 
 
Organism: H. sapiens   
Query Gene: CDK4   
Subject 
Organism: R. norvegicus   
Subject 
Chromosome: 7     
Sequence Starting Position Sequence Ending Position 
Query 1831 TGGTGGTGCACACCTGTAATCCCAGCTACTTGGGAGACTGAGGCAGGAGGATC 1883 
Sbjct 1433875 TGGTGGTGCACACCTTTAGTCCCAGC-ACTTGGGAGACTGAGGCAGTTGGATC 1433824 
 
 
Organism: H. sapiens   
Query Gene: CHIC2   
Subject 
Organism: C. lupus   
Subject 
Chromosome: 13     
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Sequence Starting Position Sequence Ending Position 
Query 66 GCGGCGGCGGCAGCGGCGTCTGTGCTTGTGGAGGTG 101 
Sbjct 2580650 GCGGCGGCGGCGGCGGCGGCCGTGCGTGTGGGGGTG 2580685 
 
 
Organism: H. sapiens   
Query Gene: CHIC2   
Subject 
Organism: M. musculus   
Subject 
Chromosome: 5     
Sequence Starting Position Sequence Ending Position 
Query 785 TGATGGAATATGTCATCCTCATAGAATTTTTA 816 
Sbjct 11161227 TGATGTAATATGTCATCCTCAT---ATTTTTA 11161199 
 
 
Organism: H. sapiens   
Query Gene: CHIC2   
Subject 
Organism: R. norvegicus   
Subject 
Chromosome: 14     
Sequence Starting Position Sequence Ending Position 
Query 1137 GAACTTAGCATaaaaaa 1153 
Sbjct 51323 GAACTTAGCATAATAAA 51339 
 
 
Organism: H. sapiens   
Query Gene: CRTC1   
Subject Organism: C. lupus   
Subject 
Chromosome: 20     
Sequence Starting Position Sequence Ending Position 
Query 2883 AGGGGAGTTTCATTGTGGttttttttt 2909 
Sbjct 7888396 AGTGGAATTTCATTGTGGTTTTTTTTT 7888370 
 
 
Organism: H. sapiens   
Query Gene: CRTC1   
Subject Organism: M. musculus   
Subject 
Chromosome: 8     
Sequence Starting Position Sequence Ending Position 
Query 5305 CTTCTATTTTAtttttttAGAGATGGGGTCTTGCTGTGTTGCCCAGGCTGGTCTCGGACT 5364 
Sbjct 8887267 CTTCACTTTCAGTTCTTTAGAGACGGTGTCTCTCT-TGCTGTCCAGGCTGGTCTGGAACT 8887325 
Query 5365 CCTGGGCTCAAGCAGTCCT 5383 
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Sbjct 8887326 CCTGGGCTCCAACAGTTCT 8887344 
 
 
Organism: H. sapiens   
Query Gene: CRTC1   
Subject 
Organism: R. norvegicus   
Subject 
Chromosome: 16     
Sequence Starting Position Sequence Ending Position 
Query 5319 ttttAGAGATGGGGTCTTGCTGTGTTGCCCAGGCTGGTCTC 5359 
Sbjct 6995555 TTTTAGAGATGGGGCCTTGTTATGCTGCCAAGGCTGGTCTC 6995595 
 
 
Organism: H. sapiens   
Query Gene: EGFR   
Subject 
Organism: C. lupus   
Subject 
Chromosome: 18     
Sequence Starting Position Sequence Ending Position 
Query 3517 GAATACATAAACCAGTCCGTTCCCAAAAGGCCCGCTGGCTCTGTGCAGAATCCTGTCTAT 3576 
Sbjct 6041172 GAATACATAAACCAGTCTGTTCCCAAAAGGCCTGCGGGTTCTGTCCAGAATCCCGTCTAT 6041231 
Query 3577 CACAATCAGCCTCTGAACCCCGCGCCCAGCAGAGACCCACACTACCAGGACCCCCACAGC 3636 
Sbjct 6041232 CACAATCAGCCTCTAAATCCAGCTCCTGCCAGAGACCCTCACTACCAAAATCCCCACAGC 6041291 
Query 3637 ACTGCAGTGGGCAACCCCGAGTATCTCAACACTGTCCAGCCCACCTGTGTCAACAGCACA 3696 
Sbjct 6041292 AACGCAGTGGACAACCCTGAGTATCTCAACAC---CCACCCCACCTGCGTCAACAGTGTC 6041348 
Query 3697 TTCGACAGCCCTGCCCACTGGGCCCAGAAAGGCAGCCACCAAATTAGCCTGGACAACCCT 3756 
Sbjct 6041349 CTCGACAGGCCCAGCCTCTGGACCCAGGAGGCCAACCACCAAATCAGCCTGGACAACCCT 6041408 
Query 3757 GACTACCAGCAGGACTTCTTTCCCAAGGAAGCCAAGCCAAATGGCATCTTTAAGGGCTCC 3816 
Sbjct 6041409 GACTACCAGCAGGACTTCTTTCCCAAGGAAGCCAAGTCCAATGGCATTTTTAAGGGCCCT 6041468 
Query 3817 ACAGCTGAAAATGCAGAATACCTAAGGGTCGCGCCACAAAGCAGTGAATTTATTGGAGCA 3876 
Sbjct 6041469 GCAGCTGAAAATGCAGACTACCTGAGGGTAGCGCCACCAAGCAGTGAGTTTATTGGAGCG 6041528 
Query 3877 TGACCACGGAGGATAGTATGAGCCCTAAAAATC-CAGACTCTTTC-GATACCCAGGACCA 3934 
Sbjct 6041529 TGACCACGGAGGATAGCCTTGGCCATAAGAGTCTCAGA-TGTTTCAGCCCCCTGGGACCC 6041587 
Query 3935 AGCCACAGCAGGTCCTCCA-TCCCAACAGCCATGCCCGCATTAGCTCTTAGACCCACAGA 3993 
Sbjct 6041588 AGTCTTGGCAGCTGCTCCAGTGCTGATA-ACATGCCCACATTAACTCTTGGACCTGTTGA 6041646 
Query 3994 CTGGTTTTGCAACGTTTACACC----GACT--------AGCCAGGAAGTAC--------- 4032 
Sbjct 6041647 CTGGTTTGGCCCTATTTGCTCCGATGGACTCATCTTTCACCCAGGATGTGCCCGCTACGT 6041706 
Query 4033 --TTCCACCTCGGGCACATTT--TGGGAAGTTGCATTCCTTTGTCTTCAAACTGTGAAGC 4088 
Sbjct 6041707 GGATGTACTTTGGGAAGAGTTACTGGGACATTCCATTCCTTTGTCTTCAAACTGTGAGGC 6041766 
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Query 4089 ATTTACAGAAACGCATCCAGCAAGAATATTGTCCCTTTGAGCAGAAATTTATCTTTCAAA 4148 
Sbjct 6041767 CTCCGCAAAAAGGCATCCAGCAAGAATATTGTCTATTTGGGCAGAAGTTCACCTTCCGAT 6041826 
Query 4149 GAGGTATATTTGa---aaaaaaaaaaaaGTATATGT--GAGGATTTTTATTGATTGGGGA 4203 
Sbjct 6041827 GAGGTATATTTGATTTAAAAAAAAAAAAAAAACTGTAAAAGGAATTTTATTGCTTGGGGA 6041886 
Query 4204 TCTTGGAG---TTTTTCATTGTCGCTATTGATTTTTACTTC-AATGGGCTCTTCCAACAA 4259 
Sbjct 6041887 CCCTTGAGGCAATTTTAATTGTCATCATTGA-TTTTATTTCTCGTGGGCTTTTCCAATGG 6041945 
Query 4260 GGAAGAAGCTTGCTGGTAGCACTTGCTACCCTGAGTTCATCCAGGCCCAACTGTGAGCAA 4319 
Sbjct 6041946 GGAAGAAGCTTGCTCATAGCACTTGCTGCACTGAGTTGATCCAGGCTCAACTGTGACCAA 6042005 
Query 4320 GGAGCACAAGCCACAAGTCTTCCAGAGGATGCTTGATTCCAGTGGTTCTGCTTCAAG--G 4377 
Sbjct 6042006 GAAGCAAGGGTCA-GAGTCTTCCAGCTAACCTTTGATTCCACTGACTCTGCTTCAAGATT 6042064 
Query 4378 CTTCCACTGCAAAACACT----------------------------------AAAGATCC 4403 
Sbjct 6042065 CTCCCACTGCAAGACAATTAAAAAAACAAAAAACAAAAAAACAAAAAAAAAAAAAGAAAC 6042124 
Query 4404 A-------AGAAGGCCTTCATGGCCCCAGCAGGCCGGATCGGTACTGTATCAAGTCATGG 4456 
Sbjct 6042125 AGAACTCTAGGAGTACTCAGAGTCCTAAGCAGGACGGATTGATACTGTAGCAAATCATAG 6042184 
Query 4457 CAGGTACAGTAGGATAAGCCACTCTG-TCCCTTCCTGGGCAAAGAAGAAACGGAGGGGAT 4515 
Sbjct 6042185 CAGGTACAAGAGGATAAGCCACTTTGAACCCTTCCTGATTGGAGAAGAAATGCAGGCG-T 6042243 
Query 4516 GGAATTCTTCCTTAGACTTACTTTTGTAAAAATGTCCCCACGGTACTTACTCCCCACTGA 4575 
Sbjct 6042244 AGACTTCTTCTTCAGACTTCTTTTTATATAAATTTCTTCATGGTACTTACTCTCTATCGG 6042303 
Query 4576 TGGACCAGTGGTTTCCAGT 4594 
Sbjct 6042304 TCGACCAGTGTTTTCTAGT 6042322 
 
 
Organism: H. sapiens   
Query Gene: EGFR   
Subject 
Organism: M. musculus   
Subject 
Chromosome: 11     
Sequence Starting Position Sequence Ending Position 
Query 3517 GAATACATAAACCAGTCCGTTCCCAAAAGGCCCGCTGGCTCTGTGCAGAATCCTGTCTAT 3576 
Sbjct 13811493 GAATATGTAAACCAATCTGTTCCCAAGAGGCCAGCAGGCTCTGTGCAGAACCCTGTCTAT 13811552 
Query 3577 CACAATCAGCCTCTGAACCCCGCGCCCAGCAGAGACCCACACTACCAGGACCCCCACAGC 3636 
Sbjct 13811553 CACAATCAGCCCCTGCATCCAGCTCCTGGAAGAGACCTGCATTATCAAAATCCCCACAGC 13811612 
Query 3637 ACTGCAGTGGGCAACCCCGAGTATCTCAACACTGTCCAGCCCACCTGTGTCAACAGCACA 3696 
Sbjct 13811613 AATGCAGTGGGCAACCCTGAGTATCTCAACACTGCCCAGCCTACCTGTCTCAGTAGTGGG 13811672 
Query 3697 TTCGACAGCCCTGCCCACTGGGCCCAGAAAGGCAGCCACCAAATTAGCCTGGACAACCCT 3756 
Sbjct 13811673 TTTAACAGCCCTGCACTCTGGATCCAGAAAGGCAGTCACCAAATGAGCCTAGACAACCCT 13811732 
Query 3757 GACTACCAGCAGGACTTCTTTCCCAAGGAAGCCAAGCCAAATGGCATCTTTAAGGGCTCC 3816 
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Sbjct 13811733 GACTACCAGCAGGACTTCTTCCCCAAGGAAACCAAGCCAAATGGCATATTTAAGGGCCCC 13811792 
Query 3817 ACAGCTGAAAATGCAGAATACCTAAGGGTCGCGCCACAAAGCAGTGAATTTATTGGAGCA 3876 
Sbjct 13811793 ACAGCTGAAAATGCAGAGTACCTACGGGTGGCACCTCCAAGCAGTGAGTTTATTGGAGCA 13811852 
Query 3877 TGAC--CACGGAGGATAGTATGAGCCCTAAAA-ATCCAGACTCTTTCGATACCCAGGACC 3933 
Sbjct 13811853 TGACAAGAAGGGGCATCATACCAGCTATAAAATGTCTGGACTTTCTAGAATCCCAGGACC 13811912 
Query 3934 AAGCCACAGCAGGTCCTCCA-TCCCAACAGCCATGCCCGCATTAGCTCTTA-GACCCACA 3991 
Sbjct 13811913 
AA-
CTATGGCAGCACCTCCACTTCTGGTAGCCATGCCCACGCTGTGTCAAATGTCA
CTCA 
13811971 
Query 3992 GACTGGTTTT---GC--AACGTTTA----CACCG--ACT-AGCCAGGAAGT---ACTTCC 4036 
Sbjct 13811972 GACTGGCTTTAAAGCATAACTCTGATGGGCTTTGTCACTGAGCCAAGAAGTGGGCCTCTC 13812031 
Query 4037 ACCTCGGGCACATTTTGGGAAGTTG------CATTCCTTTGTCTTCAAACTGTGAAGCAT 4090 
Sbjct 13812032 TCCTGATGCAC--TTTGGGAAGTTGAAGGTACATCAATTGATCTTCGAACTGTGAAGATT 13812089 
 
 
Organism: H. sapiens   
Query Gene: EGFR   
Subject 
Organism: R. norvegicus   
Subject 
Chromosome: 14     
Sequence Starting Position Sequence Ending Position 
Query 447 TACCTATGTGCAGAG 461 
Sbjct 69264 TACCTATGTGCAGAG 69250 
 
 
Organism: H. sapiens   
Query Gene: FANCA   
Subject 
Organism: R. norvegicus   
Subject 
Chromosome: 19     
Sequence Starting Position Sequence Ending Position 
Query 3310 CTCTGCGGCAGCAGCTTCCAGGCAGAACAGCCCATCA 3346 
Sbjct 3344610 CTCTGCGGCAGCAGCAACCAGGAAGATCTGCGCATCA 3344574 
 
 
Organism: H. sapiens   
Query Gene: FGFR3   
Subject 
Organism: C. lupus   
Subject 
Chromosome: 3     
Sequence Starting Position Sequence Ending Position 
Query 3954 tatat-ctatatatataATTTATTGAGTTTTTACAAGATGTA 3994 
Sbjct 26623316 TATATGCTA-ATCTATAATCTTTTGAGCTTTTACAAGATGTA 26623356 
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Organism: H. sapiens   
Query Gene: FGFR3   
Subject 
Organism: M. musculus   
Subject 
Chromosome: 5     
Sequence Starting Position Sequence Ending Position 
Query 3957 atctatatatataATTTATTGAGTTTTTACAAGATGTATT 3996 
Sbjct 10970965 ATATATATATATAATCTGT---GTTTTTACAAGATTTATT 10971001 
 
 
Organism: H. sapiens   
Query Gene: FOXO1   
Subject 
Organism: C. lupus   
Subject 
Chromosome: 25     
Sequence Starting Position Sequence Ending Position 
Query 1014 AGAATTCAATTCGTCATAATCTGTCCCTACACAGCAAGTTCATTCGTGTGCAGAATGAAG 1073 
Sbjct 701386 AGAATTCAATTCGTCATAATCTGTCCCTACATAGCAAGTTCATTCGTGTGCAGAATGAAG 701445 
Query 1074 GAACTGGAAAAAGTTCTTGGTGGATGCTCAATCCAGAGGGTGGCAAGAGCGGGAAATCTC 1133 
Sbjct 701446 GAACTGGAAAAAGTTCTTGGTGGATGCTCAATCCAGAGGGAGGCAAGAGTGGAAAATCCC 701505 
Query 1134 CTAGGAGAAGAGCTGCATCCATGGACAACAACAGTAAATTTGCTAAGAGCCGAAGCCGAG 1193 
Sbjct 701506 CCCGGAGAAGAGCTGCTTCCATGGACAACAACAGTAAATTTGCTAAGAGCCGGGGCAGAG 701565 
Query 1194 CTGCCAAGAAGAAAGCATCTCTCCAGTCTGGCCAGGAGGGTGCTGGGGACAGCCCTGGAT 1253 
Sbjct 701566 CTGCTAAGAAAAAAGCATCCCTTCAGTCTGGCCAGGAGGGTGCTGGGGACAGCCCAGGAT 701625 
Query 1254 CACAGTTTTCCAAATGGCCTGCAAGCCCTGGCTCTCACAGCAATGATGACTTTGATAACT 1313 
Sbjct 701626 CTCAGTTTTCTAAGTGGCCTGCGAGTCCAGGCTCTCACAGCAACGATGACTTTGATAACT 701685 
Query 1314 GGAGTACATTTCGCCCTCGAACTAGCTCAAATGCTAGTACTATTAGTGGGAGACTCTCAC 1373 
Sbjct 701686 GGAGTACGTTTCGCCCTCGAACTAGCTCAAATGCTAGTACTATTAGTGGGAGACTTTCTC 701745 
Query 1374 CCATTATGACCGAACAGGATGATCTTGGAGAAGGGGATGTGCATTCTATGGTGTACCCGC 1433 
Sbjct 701746 CCATTATGACCGAACAGGATGATCTTGGAGATGGCGATGTGCATTCTATGGTGTACCCAC 701805 
Query 1434 CATCTGCCGCAAAGATGGCCTCTACTTTACCCAGTCTGTCTGAGATAAGCAATCCCGAAA 1493 
Sbjct 701806 CGTCTGCTGCAAAGATGGCTTCTACTCTACCTAGCCTGTCTGAGATAAGCAATCCTGAAA 701865 
Query 1494 ACATGGAAAATCTTTTGGATAATCTCAACCTTCTCTCATCACCAACATCATTAACTGTTT 1553 
Sbjct 701866 ATATGGAAAATCTTCTGGATAATCTCAACCTTCTCTCATCACCAACGCCATTAACTGTTT 701925 
Query 1554 CGACCCAGTCCTCACCTGGCACCATGATGCAGCAGACGCCGTGCTACTCGTTTGCGCCAC 1613 
Sbjct 701926 CAACCCAGTCTTCACCTGGCACCATAATGCAACAGACACCATGCTACTCATTTGCACCGC 701985 
Query 1614 CAAACACCAGTTTGAATTCACCCAGCCCAAACTACCAAAAATATACATATGGCCAATCCA 1673 
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Sbjct 701986 CAAACACCAGTCTGAATTCACCCAGCCCAAACTACCAAAAATATACATATGGTCAGTCCA 702045 
Query 1674 GCATGAGCCCTTTGCCCCAGATGCCTATACAAACACTTCAGGACAATAAGTCGAGTTATG 1733 
Sbjct 702046 GCATGAGTCCTTTGCCCCAGATGCCTATGCAAACACTTCAGGACAACAAATCGAGCTTTG 702105 
Query 1734 GAGGTATGAGTCAGTATAACTGTGCGCCTGGACTCTTGAAGGAGTTGCTGACTTCTGACT 1793 
Sbjct 702106 GAGGTATGAATCAGTATAACTGTGCACCAGGACTCTTGAAGGAGTTGCTTACTTCTGATT 702165 
Query 1794 CTCCTCCCCATAATGACATTATGACACCAGTTGATCCTGGGGTAGCCCAGCCCAACAGCC 1853 
Sbjct 702166 CTCCTCCCCATAATGACATTATGACAGCAGTTGATCCTGGGGTCACCCAGCCCAACAGCC 702225 
Query 1854 GGGTTCTGGGCCAGAACGTCATGATGGGCCCTAATTCGGTCATGTCAACCTATGGCAGCC 1913 
Sbjct 702226 GGGTCCTTGGTCAGAATGTGTTGATGGGCCCTAATTCGGTCATGTCAACTTATGGCAGCC 702285 
Query 1914 AGGCATCTCATAACAAAATGATGAATCCCAGCTCCCATACCCACCCTGGACATGCTCAGC 1973 
Sbjct 702286 AGGCATCTCATAACAAAATGATGAGCCCCAGCTCCCACACCCACCCTGGACATAGCCAGC 702345 
Query 1974 AGACATCTGCAGTTAACGGGCGTCCCCTGCCCCACACGGTAAGCACCATGCCCCACACCT 2033 
Sbjct 702346 CAACATCTGCAGTTAATGGGCGTGCCTTGCCCCACACTGTCAACACCATGCCCCACACCT 702405 
Query 2034 CGGGTATGAACCGCCTGACCCAAGTGAAGACACCTGTACAAGTGCCTCTGCCCCACCCCA 2093 
Sbjct 702406 CGGGTATGAACCGCTTGGCCCCAGTGAAGACAGCTTTACAAGTGCCTCTGTCCCACCCCA 702465 
Query 2094 TGCAGATGAGTGCCCTGGGGGGCTACTCCTCCGTGAGCAGCTGCAATGGCTATGGCAGAA 2153 
Sbjct 702466 TGCAGATGAACACCTTGGGAGCCTACTCCTCTGTGAGCAGCTGCAATGGCTATGGAAGGA 702525 
Query 2154 TGGGCCTTCTCCACCAGGAGAAGCTCCCAAGTGACTTGGATGGCATGTTCATTGAGCGCT 2213 
Sbjct 702526 TGGGCCTGCTCCACCAGGAGAAGCTCCCCAGTGACTTGGATGGCATGTTTATTGAGCGCT 702585 
Query 2214 TAGACTGTGACATGGAATCCATCATTCGGAATGACCTCATGGATGGAGATACATTGGATT 2273 
Sbjct 702586 TGGACTGTGACATGGAGTCCATCATTCGGAACGACCTCATGGATGGAGATACTTTGGATT 702645 
Query 2274 TTAACTTTGACAATGTGTTGCCCAACCAAAGCTTCCCACACAGTGTCAAGACAACGACAC 2333 
Sbjct 702646 TTAACTTTGACAATGTGTTGCCCAACCAAAGCTTCCCGCACAGCGTCAAGACAACGACAC 702705 
Query 2334 ATAGCTGGGTGTCAGGCTGAGGGTTAGTGAG 2364 
Sbjct 702706 ATAGCTGGGTGTCAGGCTAAGAGTGAGTTAG 702736 
 
 
Organism: H. sapiens   
Query Gene: FOXO1   
Subject 
Organism: M. musculus   
Subject 
Chromosome: 3     
Sequence Starting Position Sequence Ending Position 
Query 1512 ATAAT-CTCAACCTTCT-CTCATCACCAACATCATTAAC 1548 
Sbjct 625881 ATAATGCTCATCGTCCTACTCATCACCAACATCATTAAC 625843 
 
 
Organism: H. sapiens   
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Query Gene: FOXO1   
Subject 
Organism: R. norvegicus   
Subject 
Chromosome: 2     
Sequence Starting Position Sequence Ending Position 
Query 3453 ATGTTTTTATGTATGTATT 3471 
Sbjct 16879 ATGTATTTATGTATGTATT 16897 
 
 
Organism: H. sapiens   
Query Gene: HOXC13   
Subject 
Organism: C. lupus   
Subject 
Chromosome: 27     
Sequence Starting Position Sequence Ending Position 
Query 29 ggggggaggggaAACAGGAGCGAGGTGTCTCCCTAGCTCGCTGCCTCTGGCAAGTGGAGT 88 
Sbjct 1323355 GGAGGGAGGGGAGA--GGAGCGAGGTGTCTCCCTAGCTCGCTGCCTCTGGCAAGTGGAGT 1323298 
Query 89 TTTTAAAAAGCTCCAGCAGATCATGTCATGACGACTTCGCTGCTCCTGCATCCACGCTGG 148 
Sbjct 1323297 TTTTAGAAAGTTCGCGCAGACCATGTCATGACCACTTCGCTGCTCCTGCATCCGCGCTGG 1323238 
Query 149 CCGGAGAGCCTTATGTACGTCTATGAGGACAgcgcggcggagagcggcatcggcggcggc 208 
Sbjct 1323237 CCGGAGAGCCTTATGTACGTCTATGAGGACAGCGCGGCGGAG---------GGCGGCGGC 1323187 
Query 209 ggcggaggaggaggcggcggcacgggcggagcggggggtggctgcagcggagcgagcccc 268 
Sbjct 1323186 GGCGG---------CGGCGGCGCGGGCGGCGCGGGGGGCGGCTGCAGCGGAGCGAGCCCC 1323136 
Query 269 ggcAAAGCCCCGAGCATGGATGGTCTGGGCAGCAGCTGCCCGGCCAGCCACTGCCGCGAC 328 
Sbjct 1323135 GGCAAGGCCCCCAGCATGGACGGGCTGGGCAGCGGCTGCCCCGCCAGCCACTGCCGCGAC 1323076 
Query 329 CTGCTTCCGCACCCCGTGCTGGGCCGCCCGCCGGCTCCCCTGGGCGCCCCTCAGGGCGCC 388 
Sbjct 1323075 CTGCTCCCGCACCCCGTGCTGGGCCGCCCGCCCGCCCCCCTGGGCGCCCCGCAGGGCGCC 1323016 
Query 389 GTCTATACGGACATCCCGGCCCCGGAGGCGGCGCGCCAGTGTGCCCCGCCGCCCGCACCC 448 
Sbjct 1323015 GTCTACACGGACATCCCGGCCCCGGAGGCGGCGCGCCAGTGCGCCCCGCCGCCGGCGCCC 1322956 
Query 449 CCCACCTCGTCCAGCGCCACCCTGGGCTACGGCTACCCCTTCGGGGGCAGCTACTACGGC 508 
Sbjct 1322955 CCCACCTCGTCCAGCGCCACCCTGGGCTACGGCTACCCGTTCGGGGGCAGCTACTACGGC 1322896 
Query 509 TGCCGCCTGTCGCACAACGTGAACCTGCAGCAGAAGCCTTGCGCCTACCACCCGGGCGAT 568 
Sbjct 1322895 TGCCGCCTGTCGCACAACGTGAACCTGCAGCAGAAGCCCTGCGCCTACCACCCGGGCGAC 1322836 
Query 569 AAATACCCGGAGCCGTCGGGCGCCCTGCCCGGTGACGACCTGTCCTCTAGGGCCAAGGAG 628 
Sbjct 1322835 AAGTACGCGGAGCCGTCGGGCGCCCTGCCCGGGGACGACCTGTCCTCCAGGGCCAAGGAG 1322776 
Query 629 TTCGCCTTCTACCCCAGCTTCGCCAGCTCCTACCAGGCGATGCCCGGCTACCTGGACGTG 688 
Sbjct 1322775 TTCGCCTTCTACCCCAGCTTCGCCAGCTCCTACCAGGCGGTGCCCGGCTACCTGGACGTG 1322716 
Query 689 TCGGTGGTGCCCGGGATCAGCGGGCACCCGGAGCCGCGTCACGACGCCCTCATCCCCGTC 748 
Sbjct 1322715 TCGGTGGTGCCCGGCATCAGCGGGCACCCGGAGCCGCGCCACGACGCGCTCA 1322656 
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TCCCCGTC 
Query 749 GAAGGCTACCAGCACTGGGCTCTCTCCAATGGCTGGGACAGTCAGGTGTACTGCTCCAAG 808 
Sbjct 1322655 GAAGGCTACCAGCACTGGGCGCTCTCCAACGGCTGGGACAGTCAGGTGTACTGCTCCAAG 1322596 
Query 809 GAGCAGTCGCAGTCCGCCCACCTCTGGAAGTCTCCCTTCCCAG 851 
Sbjct 1322595 GAGCAGTCGCAGTCCGCGCACCTCTGGAAGTCCCCCTTCCCAG 1322553 
 
 
Organism: H. sapiens   
Query Gene: HOXC13   
Subject 
Organism: M. musculus   
Subject 
Chromosome: 15     
Sequence Starting Position Sequence Ending Position 
Query 2274 TTTTTAAAAAATGTTGTGTATCTGTATATAGTATT 2308 
Sbjct 2927077 TTTTTAAAAAATGTCACATATCTGTATAGTGTATT 2927043 
 
 
Organism: H. sapiens   
Query Gene: HOXC13   
Subject 
Organism: R. norvegicus   
Subject 
Chromosome: 7     
Sequence Starting Position Sequence Ending Position 
Query 921 AGGTGCAGCTGAAGGAGCTAGAGA 944 
Sbjct 374621 AGGTGCAGCTGAAGGGGCTGGAGA 374598 
 
 
Organism: H. sapiens   
Query Gene: MET   
Subject 
Organism: C. lupus   
Subject 
Chromosome: 14     
Sequence Starting Position Sequence Ending Position 
Query 172 AGATAAACCTCTCATAATGAAGGCCCCCGCTGTGCTTGCACCTGGCATCCTCGTGCTCCT 231 
Sbjct 55626338 AGATATGCTTCTCACCATGAAGGCTCCTGCTGTGCTTGCACCTGGCATCCTTGTGCTTCT 55626397 
Query 232 GTTTACCTTGGTGCAGAGGAGCAATGGGGAGTGTAAAGAGGCACTAGCAAAGTCCGAGAT 291 
Sbjct 55626398 GTTTACCTTGGTGCAGAAGAGCTATGGGGAGTGCAAAGAGGCACTAGTAAAGTCTGAGAT 55626457 
Query 292 GAATGTGAATATGAAGTATCAGCTTCCCAACTTCACCGCGGAAACACCCATCCAGAATGT 351 
Sbjct 55626458 GAATGTGAACATGAAGTATCAGCTTCCCAACTTCACTGCCGAAACACCCATCCAGAATGT 55626517 
Query 352 CATTCTACATGAGCATCACATTTTCCTTGGTGCCACTAACTACATTTATGTTTTAAATGA 411 
Sbjct 55626518 TGTTTTACACAAGCATCATATTTACCTTGGTGCAGTTAACTATATTTACGTTTTAAATGA 55626577 
Query 412 GGAAGACCTTCAGAAGGTTGCTGAGTACAAGACTGGGCCTGTGCTGGAACACCCAGATTG 471 
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Sbjct 55626578 CAAAGACCTTCAGAAGGTTGCTGAGTACAAGACTGGGCCCGTGCTGGAACACCCAGATTG 55626637 
Query 472 TTTCCCATGTCAGGACTGCAGCAGCAAAGCCAATTTATCAGGAGGTGTTTGGAAAGATAA 531 
Sbjct 55626638 TTCCCCATGTCAGGACTGCAGCCACAAAGCCAATTTATCAGGTGGTGTTTGGGAAGATAA 55626697 
Query 532 CATCAACATGGCTCTAGTTGTCGACACCTACTATGATGATCAACTCATTAGCTGTGGCAG 591 
Sbjct 55626698 CATCAACATGGCTCTGCTTGTTGACACATACTACGATGACCAACTCATTAGCTGTGGCAG 55626757 
Query 592 CGTCAACAGAGGGACCTGCCAGCGACATGTCTTTCCCCACAATCATACTGCTGACATACA 651 
Sbjct 55626758 TGTCCACAGAGGGACCTGCCAGCGACATATCCTTCCACCCAGCAATATTGCTGACATACA 55626817 
Query 652 GTCGGAGGTTCACTGCATATTCTCCCCACAGATAGA---AGAGCCCAGCCAGTGTCCTGA 708 
Sbjct 55626818 GTCGGAAGTGCATTGCATGTACTCCTCACAGGCAGACGAAGAGCCCAGCCAGTGCCCTGA 55626877 
Query 709 CTGTGTGGTGAGCGCCCTGGGAGCCAAAGTCCTTTCATCTGTAAAGGACCGGTTCATCAA 768 
Sbjct 55626878 CTGTGTGGTGAGTGCTCTAGGAACCAAAGTCCTGATATCAGAAAAGGACCGGTTCATCAA 55626937 
Query 769 CTTCTTTGTAGGCAATACCATAAATTCTTCTTATTTCCCAGATCATCCATTGCATTCGAT 828 
Sbjct 55626938 CTTCTTCGTAGGCAATACCATAAATTCCTCGGACCATCCAGATCATTCATTGCATTCGAT 55626997 
Query 829 ATCAGTGAGAAGGCTAAAGGAAACGAAAGATGGTTTTATGTTTTTGACGGACCAGTCCTA 888 
Sbjct 55626998 ATCGGTGAGAAGGCTAAAGGAAACGCAAGATGGGTTCAAGTTTTTGACAGACCAGTCTTA 55627057 
Query 889 CATTGATGTTTTACCTGAGTTCAGAGATTCTTACCCCATTAAGTATGTCCATGCCTTTGA 948 
Sbjct 55627058 CATTGATGTTCTACCGGAGTTCAGAGACTCCTACCCCATTAAATATGTCCACGCCTTTGA 55627117 
Query 949 AAGCAACAATTTTATTTACTTCTTGACGGTCCAAAGGGAAACTCTAGATGCTCAGACTTT 1008 
Sbjct 55627118 AAGCAACCACTTTATTTACTTTTTGACAGTCCAGCGAGAAACTCTAGATGCTCAGACTTT 55627177 
Query 1009 TCACACAAGAATAATCAGGTTCTGTTCCATAAACTCTGGATTGCATTCCTACATGGAAAT 1068 
Sbjct 55627178 TCACACGAGAATAATCAGGTTCTGTTCTGTAGACTCTGGATTGCATTCCTACATGGAAAT 55627237 
Query 1069 GCCTCTGGAGTGTATTCTCACAGAAAAGAGAAAAAAGAGATCCACAAAGAAGGAAGTGTT 1128 
Sbjct 55627238 GCCTCTGGAGTGTATTCTCACGGAAAAGAGAAGAAAGAGATCCACAAGGGAGGAAGTGTT 55627297 
Query 1129 TAATATACTTCAGGCTGCGTATGTCAGCAAGCCTGGGGCCCAGCTTGCTAGACAAATAGG 1188 
Sbjct 55627298 TAATATTCTCCAAGCTGCATATGTCAGTAAGCCTGGGGCCCATCTCGCTAAACAAATAGG 55627357 
Query 1189 AGCCAGCCTGAATGATGACATTCTTTTCGGGGTGTTCGCACAAAGCAAGCCAGATTCTGC 1248 
Sbjct 55627358 TGCCAACCTGAATGATGACATTCTCTATGGAGTGTTCGCACAAAGCAAGCCAGATTCTGC 55627417 
Query 1249 CGAACCAATGGATCGATCTGCCATGTGTGCATTCCCTATCAAATATGTCAACGACTTCTT 1308 
Sbjct 55627418 TGAACCAATGAATCGCTCTGCCGTCTGTGCGTTCCCTATCAAATATGTCAATGAATTCTT 55627477 
Query 1309 CAACAAGATCGTCAACAAAAACAATGTGAGATGTCTCCAGCATTTTTACGGACCCAATCA 1368 
Sbjct 55627478 CAACAAGATCGTCAACAAAAACAATGTGAGATGTCTTCAGCACTTTTATGGACCCAACCA 55627537 
Query 1369 TGAGCACTGCTTTAATAGG 1387 
Sbjct 55627538 CGAACACTGCTTTAATAGG 55627556 
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Query Gene: MET   
Subject 
Organism: M. musculus   
Subject 
Chromosome: 6     
Sequence Starting Position Sequence Ending Position 
Query 172 AGATAAACCTCTCATAATGAAGGCCCCCGCTGTGCTTGCACCTGGCATCCTCGTGCTCCT 231 
Sbjct 14441225 AGATCAACTCCTCACAATGAAGGCTCCCACCGTGCTGGCACCTGGCATTCTGGTGCTGCT 14441284 
Query 232 GTTTACCTTGGTGCAGAGGAGCAATGGGGAGTGTAAAGAGGCACTAGCAAAGTCCGAGAT 291 
Sbjct 14441285 GTTGTCCTTGGTGCAGAGGAGCCATGGGGAGTGCAAGGAGGCCCTAGTGAAGTCTGAGAT 14441344 
Query 292 GAATGTGAATATGAAGTATCAGCTTCCCAACTTCACCGCGGAAACACCCATCCAGAATGT 351 
Sbjct 14441345 GAACGTGAACATGAAGTATCAGCTCCCCAACTTCACGGCAGAAACCCCCATCCAGAATGT 14441404 
Query 352 CATTCTACATGAGCATCACATTTTCCTTGGTGCCACTAACTACATTTATGTTTTAAATGA 411 
Sbjct 14441405 CGTCCTACACGGCCATCATATTTATCTCGGAGCCACAAACTACATTTATGTTTTAAATGA 14441464 
Query 412 GGAAGACCTTCAGAAGGTTGCTGAGTACAAGACTGGGCCTGTGCTGGAACACCCAGATTG 471 
Sbjct 14441465 CAAAGACCTTCAGAAGGTATCCGAATTCAAGACCGGGCCCGTGTTGGAACACCCAGATTG 14441524 
Query 472 TTTCCCATGTCAGGACTGCAGCAGCAAAGCCAATTTATCAGGAGGTGTTTGGAAAGATAA 531 
Sbjct 14441525 TTTACCTTGTCGGGACTGCAGCAGCAAAGCCAATTCATCAGGAGGGGTTTGGAAAGACAA 14441584 
Query 532 CATCAACATGGCTCTAGTTGTCGACACCTACTATGATGATCAACTCATTAGCTGTGGCAG 591 
Sbjct 14441585 CATCAACATGGCTCTGCTTGTTGACACATACTATGATGATCAACTCATTAGCTGTGGCAG 14441644 
Query 592 CGTCAACAGAGGGACCTGCCAGCGACATGTCTTTCCCCACAATCATACTGCTGACATACA 651 
Sbjct 14441645 TGTCAACAGAGGGACTTGCCAGCGGCATGTCCTTCCTCCTGACAATTCTGCTGACATCCA 14441704 
Query 652 GTCGGAGGTTCACTGCATATTCTCCCCACAGATAGAAGAGCCCAGCCAGTGTCCTGACTG 711 
Sbjct 14441705 GTCTGAGGTCCACTGCATGTTCTCCCCAGA---AGAGGAGTCAGGGCAGTGTCCTGACTG 14441761 
Query 712 TGTGGTGAGCGCCCTGGGAGCCAAAGTCCTTTCATCTGTAAAGGACCGGTTCATCAACTT 771 
Sbjct 14441762 TGTAGTGAGTGCCCTCGGAGCCAAAGTCCTCCTGTCGGAAAAGGACCGGTTCATCAATTT 14441821 
Query 772 CTTTGTAGGCAATACCATAAATTCTTCTTATTTCCCAGATCATCCATTGCATTCGATATC 831 
Sbjct 14441822 CTTTGTGGGGAATACGATCAATTCCTCCTATCCTCCTGGTTATTCACTGCATTCGATATC 14441881 
Query 832 AGTGAGAAGGCTAAAGGAAACGAAAGATGGTTTTATGTTTTTGACGGACCAGTCCTACAT 891 
Sbjct 14441882 GGTGAGACGGCTGAAGGAAACCCAAGATGGTTTTAAGTTTTTGACAGACCAGTCCTATAT 14441941 
Query 892 TGATGTTTTACCTGAGTTCAGAGATTCTTACCCCATTAAGTATGTCCATGCCTTTGAAAG 951 
Sbjct 14441942 TGATGTCTTACCAGAATTCCAAGATTCCTACCCCATAAAGTACATACATGCCTTCGAAAG 14442001 
Query 952 CAACAATTTTATTTACTTCTTGACGGTCCAAAGGGAAACTCTAGATGCTCAGACTTTTCA 1011 
Sbjct 14442002 CAACCATTTTATTTACTTTCTGACTGTCCAAAAGGAAACTCTAGATGCTCAGACTTTTCA 14442061 
Query 1012 CACAAGAATAATCAGGTTCTGTTCCATAAACTCTGGATTGCATTCCTACATGGAAATGCC 1071 
Sbjct 14442062 TACAAGAATAATCAGGTTCTGTTCCGTAGACTCTGGGTTGCACTCCTACATGGAAATGCC 14442121 
Query 1072 TCTGGAGTGTATTCTCACAGAAAAGAGAAAAAAGAGATCCACAAAGAAGGAAGTGTTTAA 1131 
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Sbjct 14442122 CCTGGAATGCATCCTGACAGAAAAAAGAAGGAAGAGATCCACAAGGGAAGAAGTGTTTAA 14442181 
Query 1132 TATACTTCAGGCTGCGTATGTCAGCAAGCCTGGGGCCCAGCTTGCTAGACAAATAGGAGC 1191 
Sbjct 14442182 TATCCTCCAAGCCGCGTATGTCAGTAAACCAGGGGCCAATCTTGCTAAGCAAATAGGAGC 14442241 
Query 1192 CAGCCTGAATGATGACATTCTTTTCGGGGTGTTCGCACAAAGCAAGCCAGATTCTGCCGA 1251 
Sbjct 14442242 TAGCCCTTCTGATGACATTCTCTTCGGGGTGTTTGCACAAAGCAAGCCAGATTCTGCTGA 14442301 
Query 1252 ACCAATGGATCGATCTGCCATGTGTGCATTCCCTATCAAATATGTCAACGACTTCTTCAA 1311 
Sbjct 14442302 ACCTGTGAATCGATCAGCAGTCTGTGCATTCCCCATCAAATATGTCAATGACTTCTTCAA 14442361 
Query 1312 CAAGATCGTCAACAAAAACAATGTGAGATGTCTCCAGCATTTTTACGGACCCAATCATGA 1371 
Sbjct 14442362 CAAGATTGTCAACAAAAACAACGTGAGATGTCTCCAGCATTTTTACGGACCCAACCATGA 14442421 
Query 1372 GCACTGCTTTAATAGG 1387 
Sbjct 14442422 GCACTGTTTCAATAGG 14442437 
 
 
Organism: H. sapiens   
Query Gene: MET   
Subject 
Organism: R. norvegicus   
Subject 
Chromosome: 4     
Sequence Starting Position Sequence Ending Position 
Query 5134 CCTGGACTCAAG---AAATCCACCCACCTCAGCCTCCCAAAGTGCTAGGATTACAGGCAT 5190 
Sbjct 4436901 CCTGGTCTCAAAGTCAGATCCACCTGCCTCTGCCTCCCAA-GTGCTAGGATTAAAGGTGT 4436959 
Query 5191 GAGCCAC 5197 
Sbjct 4436960 GAGCCAC 4436966 
 
 
Organism: H. sapiens   
Query Gene: MYCN   
Subject 
Organism: C. lupus   
Subject 
Chromosome: 17     
Sequence Starting Position Sequence Ending Position 
Query 1521 CAGATGATGAAGATGATGAAGAGGAAGATGAAGAGGAAGAAATCGACGTGGTCACTGTGG 1580 
Sbjct 11722699 CAGATGACGAAGATGATGAAGAGGAAGACGAGGAAGAGGAAATTGACGTGGTGACCGTGG 11722758 
Query 1581 AGAAGCGGCGTTCCTCCTCCAACACCAAGGCTGTCACCACATTCACCATCACTGTGCGTC 1640 
Sbjct 11722759 AGAAGCGGCGGTCCTCCTCCCACAGCAAGGCGGTCACCACCTTCACCATCACTGTGCGCC 11722818 
Query 1641 CCAAGAACGCAGCCCTGGGTCCCGGGAGGGCTCAGTCCAGCGAGCTGATCCTCAAACGAT 1700 
Sbjct 11722819 CCAAGAACGCCGCCCTGGGCCCGGGGAGGGCGCAGTCGGGTGAGCTGATCCTCAAACGCT 11722878 
Query 1701 GCCTTCCCATCCACCAGCAGCACAACTATGCCGCCCCCTCTCCCTACGTGGAGAGTGAGG 1760 
Sbjct 11722879 GTGTCCCCATCCACCAGCAGCACAACTACGCCGCCCCCTCTCCGTACGTGGAGAGCGAGG 11722938 
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Query 1761 ATGCACCCCCACAGAAGAAGATAAAGAGCGAGGCGTCCCCACGTCCGCTCAAGAGTGTCA 1820 
Sbjct 11722939 ATGTGCCACCCCAGAAGAAGATCAAGAGCGAAGCATCCCCCCGCCCCCTCAAGAGTGTCA 11722998 
Query 1821 TCCCCCCAAAGGCTAAGAGCTTGAGCCCCCGAAACTCTGACTCGGAGGACAGTGAGCGTC 1880 
Sbjct 11722999 TCCCCCCGAAGGCCAAGAGCTTGAGTCCCCGCAACTCCGACTCGGAGGACAGCGAGCGGC 11723058 
Query 1881 GCAGAAACCACAACATCCTGGAGCGCCAGCGCCGCAACGACCTTCGGTCCAGCTTTCTCA 1940 
Sbjct 11723059 GCCGCAACCACAACATTCTGGAACGCCAGCGCCGAAATGACCTGCGCTCCAGCTTCCTCA 11723118 
Query 1941 CGCTCAGGGACCACGTGCCGGAGTTGGTAAAGAATGAGAAGGCCGCCAAGGTGGTCATTT 2000 
Sbjct 11723119 CGCTCAGGGACCACGTGCCAGAGCTGGTGAAGAACGAGAAGGCCGCCAAGGTGGTCATTT 11723178 
Query 2001 TGAAAAAGGCCACTGAGTATGTCCACTCCCTCCAGGCCGAGGAGCACCAGCTTTTGCTGG 2060 
Sbjct 11723179 TGAAAAAGGCCACCGAGTACGTCCACTCCCTGCAGGCCGAGGAGCAGCAGCTTTTGCTGG 11723238 
Query 2061 AAAAGGAAAAATTGCAGGCAAGACAGCAGCAGTTGCTAAAGAAAATTGAACACGCTCGGA 2120 
Sbjct 11723239 AGAAGGAGAAGTTGCAGGCAAGACAGCAGCAGTTGCTAAAGAAAATTGAACACGCGCGGA 11723298 
Query 2121 CTTGCTAGACGCTTCTCAAAACTGGACAGTCACT--GCCACTTTGCACATTTTGAttttt 2178 
Sbjct 11723299 CTTGCTAAACGTCTCTCGGAACCGGACAGTCACTCTGCCACTTTGCACATTTTGATTTTT 11723358 
Query 2179 ttttt----AAACAAACATTGTGTTGACATTAAGAATGTTGGTTTACTTTCAAATCGGTC 2234 
Sbjct 11723359 TTTTTTTTTAAACAAACATTGTGTTGACATTAAGAATGTTGGTTTACTTTCAAATCGGTC 11723418 
Query 2235 CCCT--------GTCGAGTTCGGCTCTGGGTGGGCAGTAGGACCACCAGTGTGGGGTTCT 2286 
Sbjct 11723419 CCCCCCTCCCCCGTCGAGTTTGGATCTGGGTGGGGAGCAGGACCTCCGGAGAGGG----- 11723473 
Query 2287 GCTGGGACCTTGGAGAGCCTGCATCCCAGGATGCTGGGTGGCCCTGCAGCCT----CCTC 2342 
Sbjct 11723474 -------CCG------GCCTG-ATG---GGATGCTGGGTGGCCCTTCGCGCTTTCCCCTC 11723516 
Query 2343 CACCTCACCTCCATGACAGCGCTAAACGTTGGTGACGGTTGGGAGCCTCTGGGGCTGTTG 2402 
Sbjct 11723517 CGTGTCCCCTCCGAGACCGCGGTCGAAGTTCGTGACAGTCGGGAGCCTCTGGG-CTGTTG 11723575 
Query 2403 AAGTCACCTTGTGTGTTCCAAGTTTCCAAACAACAGAAA-GTCATTCCTTCTTTTTAAAA 2461 
Sbjct 11723576 AAGTCACCTTGTTGGTTCCAAGTTTCCAAACAACAGAAAAGTCATTCCTT---TTTAAAA 11723632 
Query 2462 TGGTGCTTAAGTTCCAGCAGATGCCACATAAGGGGTTTGCCATTTGATA-CCCCTGGGGA 2520 
Sbjct 11723633 TGGTGCTTAAGTTCCAGCAGATGTCACAGAAGGGGTTTGCCATTTGATAACCCCTGGGGA 11723692 
Query 2521 ACATTTCTGTAAATACCATTGACACATCCGCCTTTTGTATACATCCTGGGTAATGAGAGG 2580 
Sbjct 11723693 ACATTTCTGTAAATACCATTGACACACCCGCCTTTTGTATACGTCCTGGGTAATGAGAGG 11723752 
Query 2581 TGGCTTTTGCGGCCAGTATTAGACTGGAAGTTCATACCTAAGTACTGTAATAATACCTCA 2640 
Sbjct 11723753 TGGCTTTTGCGGCCAGTATTAGACTGGAAGTTCATACCTAAGTACTGTAAT---ACCTCA 11723809 
Query 2641 ATGTTTGAGGAGCATGTTTTGTATACAAATATATTGTTAATCTCTGTTATGTACTGTACT 2700 
Sbjct 11723810 ATGTTTGAGGAGCATGTTTTGTATACAAATATATTGTTAATCTCTGTTATGTACTGTACT 11723869 
Query 2701 AATTCTTACACTGCCTGTATACTTTAGTATGACGCTGATACATAACTAAATTTGATACTT 2760 
Sbjct 11723870 AATTCTTACACTGCCTGTATACTTTAGTATGATGCTGATACATAACTAAATTTGATACTT 11723929 
Query 2761 ATATTTTCGTATGAAAATGAGTTGTGAAAGTTTTGAGTAGATATTACTTTATCACTTTTT 2820 
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Sbjct 11723930 ATATTTTCGTATGAAAATGAGTTGTGAAAGTTTTGAGTAGATATTACTTTATCACTTTTT 11723989 
Query 2821 GAACTAAGAAACTTTTGTAAAGAAATTTACTATATATATATGCCTTTTTCCTAGCCTGTT 2880 
Sbjct 11723990 GAACTAAGAAACTTTTGTAAAGAAATTTACTATATATATATGCCTTTTTCCTAGCCTGTT 11724049 
Query 2881 TCTTCCTGTTAATGTATTTGTTCATGTTTGGTGCATAGAACTGGGTAAATGCAAAGTTCT 2940 
Sbjct 11724050 TCTTCCTGTTAATGTATTTGTTCATGTTTGGTGCATAGAACTGGGTAAATGCAAAGTTCT 11724109 
Query 2941 GTGTTTAATTTCTTCAAAATGTATATATTTAGTGCTGCATCTTATAGCACTTTGAAATAC 3000 
Sbjct 11724110 GTGTTTAATTTCTTCAAAATGTATATATTTAGTGCTGCATCTTATAGCACTTTGAAATAC 11724169 
Query 3001 CTCATGTTTATGAAAATAAATAGCTTAAAATTAAATGa 3038 
Sbjct 11724170 CTCATGTTTATGAAAATAAATAGC----AATTAAATGA 11724203 
 
 
Organism: H. sapiens   
Query Gene: MYCN   
Subject 
Organism: M. musculus   
Subject 
Chromosome: 12     
Sequence Starting Position Sequence Ending Position 
Query 1520 TCAGATGATGAAGATGATGAAGAGGAAGATGAAGAGGAAGAAATCGACGTGGTCACTGTG 1579 
Sbjct 9937614 TCAGATGATGAGGATGACGAGGAGGAAGATGAAGAGGAGGAAATCGATGTGGTCACCGTA 9937555 
Query 1580 GAGAAGCGGCGTTCCTCCTCCAACACCAAGGCTGTCACCACATTCACCATCACTGTGCGT 1639 
Sbjct 9937554 GAGAAGAGACGTTCCTCCTCTAACAACAAGGCGGTAACCACTTTCACGATCACTGTGCGT 9937495 
Query 1640 CCCAAGAACGCAGCCCTGGGTCCCGGGAGGGCTCAGTCCAGCGAGCTGATCCTCAAACGA 1699 
Sbjct 9937494 CCCAAGACCTCCGCTCTGGGCCTGGGGCGAGCACAGCCTGGCGAGCTGATCCTCAAGCGC 9937435 
Query 1700 TGCCTTCCCATCCACCAGCAGCACAACTATGCCGCCCCCTCTCCCTACGTGGAGAGTGAG 1759 
Sbjct 9937434 TGTGTTCCCATCCATCAGCAGCACAACTATGCTGCACCCTCACCCTACGTGGAGAGCGAG 9937375 
Query 1760 GATGCACCCCCACAGAAGAAGATAAAGAGCGAGGCGTCCCCACGTCCGCTCAAGAGTGTC 1819 
Sbjct 9937374 GACGCGCCCCCGCAGAAAAAGATCAAGAGCGAGGCTTCTCCACGCCCCCTCAAAAGTGTT 9937315 
Query 1820 ATCCCCCCAAAGGCTAAGAGCTTGAGCCCCCGAAACTCTGACTCGGAGGACAGTGAGCGT 1879 
Sbjct 9937314 GTTCCAGCAAAAGCGAAGAGCCTGAGCCCCCGAAACTCAGACTCGGAGGACAGCGAGCGC 9937255 
Query 1880 CGCAGAAACCACAACATCCTGGAGCGCCAGCGCCGCAACGACCTTCGGTCCAGCTTTCTC 1939 
Sbjct 9937254 CGCCGCAACCACAACATCCTGGAGCGTCAACGCCGGAACGACCTGCGCTCCAGCTTCCTG 9937195 
Query 1940 ACGCTCAGGGACCACGTGCCGGAGTTGGTAAAGAATGAGAAGGCCGCCAAGGTGGTCATT 1999 
Sbjct 9937194 ACGCTCAGGGACCATGTGCCTGAGCTGGTGAAGAACGAGAAGGCCGCCAAGGTGGTCATC 9937135 
Query 2000 TTGAAAAAGGCCACTGAGTATGTCCACTCCCTCCAGGCCGAGGAGCACCAGCTTTTGCTG 2059 
Sbjct 9937134 TTGAAAAAGGCCACCGAGTACGTGCACGCCCTACAGGCCAACGAGCACCAGCTCCTGCTG 9937075 
Query 2060 GAAAAGGAAAAATTGCAGGCAAGACAGCAGCAGTTGCTAAAGAAAATTGAACACGCTCGG 2119 
Sbjct 9937074 GAAAAGGAGAAACTGCAGGCGAGGCAGCAGCAGTTGCTAAAGAAGATCGAACACGCTCGG 9937015 
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Query 2120 ACTTGCTAGACGCTTCTCAAAACTGGACAGTCACTGCCACTTTGCACATTTTGAtttttt 2179 
Sbjct 9937014 ACTTGCTAAACGTTTCCCACAC--GGACAGTCACTGCCACTTTGCACATTTTGATTTTTT 9936957 
Query 2180 tttt-----AAACAAACATTGTGTTGACATTAAGAATGTTGGTTTACTTTCAAATCGGTC 2234 
Sbjct 9936956 TTTTTTTTTAAACAAACATTGTGTTGACATTAAGAATGTTGGTTTACTTTCAAATTGGTC 9936897 
Query 2235 CCCTGTCGAGTTCGGCTCTGGGTGGGCAGTAGGACCACCAGTGTGGGGTTCTGCTGGGAC 2294 
Sbjct 9936896 CCCTGTCGAGTCTGGATCTGGGTAGGGGGCAGGAC-AC------GGGGTTCTGCCATGAC 9936844 
Query 2295 CTTGGAGAGC---CTGCATCCCAGGATGCTGGGTGGCCCTGCAGCCTCCTCCACCTCACC 2351 
Sbjct 9936843 CTTGGAAAAAAAACTGACTTATGGGATGCTGGGTGGCTTGTTTTCCTCCTCCATATCACC 9936784 
Query 2352 TCCATGACAGCGCTAAACGTTGGTGACGGTTGGGAGCCTCTGG-GGCTGTTGAAGTCACC 2410 
Sbjct 9936783 TGG-TGACAGCCGTGGAAGTTCGGGACACTAAGGAGCTTCAGGAGGCTGT-GAAGTCACC 9936726 
Query 2411 TTGTGT-GTTCCAAGTTTCCAAACAACAGAAAGTCATTCCTTCTTTTTAAAATGGTGCTT 2469 
Sbjct 9936725 TTGTTCCGGTCCAAGATTCCAAACAG-----AGTCATTCCTTCTTTTTACAATGGTGCTT 9936671 
Query 2470 AAGTTCCAGCAGATGCCACATAAGGGGT--TTGCCATTTGATACCCCTGGGGAACATTTC 2527 
Sbjct 9936670 AAGTTCCAGCAAATGCCACAGAAGGGGGGGTTGCCATTTGATGCCCCTGGG-AACACTTG 9936612 
Query 2528 TGTAAATACCATTGACACATCCGCCTTTTGTATACATCCTGGGTAATGAGAGGTGGCTTT 2587 
Sbjct 9936611 TGTAAATACCATTGATACACCCGCCTTTTGTATACGTCCTGGGTAATGAGAGGTGGCTCT 9936552 
Query 2588 TGCGGCCAGTATTAGACTGGAAGTTCATACCTAAGTACTGTAATAATACCTCAATGTTTG 2647 
Sbjct 9936551 TGCGGCCAGTATTAGACTGGAAGTTCACACCTAAGTACTGTAAGAATACCTCAATGTTTG 9936492 
Query 2648 AGGAGCATGTTTTGTATACAAATATATTGTTAATCTCTGTTATGTACTGTACTAATTCTT 2707 
Sbjct 9936491 AGGGGCATGTTTTGTATACAAATATATTGTTAATCT--GTTATGTACTGTACTAATTCCT 9936434 
Query 2708 ACACTGCCTGTATACTTTAGTATGACGCTGATACATAACTAAATTTGATACTTATATTTT 2767 
Sbjct 9936433 ACACGGCCTGTATACTTTAGTATGACGCTGATACATAACTAAATTTGATACTTATATTTT 9936374 
Query 2768 CGTATGAAAATGAGTTGTGAAAGTTTTGAGTAGATATTACTTTATCACTTTTTGAACTAA 2827 
Sbjct 9936373 CGTATGAAAATGAGTTGTGGAAGTTTTGAGTAGATATTACTTTATCACTTTTTGAACTAA 9936314 
Query 2828 GAAACTTTTGTAAAGAAATTT-ACTATATATATATG--CCTTTTT--CCTAGCCTGTTTC 2882 
Sbjct 9936313 GAAACTTTTGTAAAGAAATTTTACTATATATATATATTCCTTTTTTTCCTAGCCTGTTTC 9936254 
Query 2883 TTCCTG--TTAATGTATTTGTTCATGTTTGGTGCATAGAACTGGGTAAA--TGCAAAGTT 2938 
Sbjct 9936253 TTCCTTGTTTACTGTATTTGTTCATGTTTGGTGCATAGAACTGGGTAAAATGGCAAAGTT 9936194 
Query 2939 CTGTGTTTAATTTCTTCAAAATGTATATATTTAGTGCTGCATCTTATAGCACTTTGAAAT 2998 
Sbjct 9936193 CTGTGTTTAATTTCTTCAAAATGTATATATTTAGTGCTGCACCTTAGAGCACTTTGAAAT 9936134 
Query 2999 ACCTCATGTTTATGAAAATAAATAGCTTAAAATTAAATGa 3038 
Sbjct 9936133 ACCTCATGTTTATGAAAATAAATAGC----AATTAAATGA 9936098 
 
 
Organism: H. sapiens   
Query Gene: MYCN   
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Subject 
Organism: R. norvegicus   
Subject 
Chromosome: 6     
Sequence Starting Position Sequence Ending Position 
Query 1522 AGATGATGAAGATGATGAAGAGGAAGATGAAGAGGAAGA 1560 
Sbjct 292893 AGAAGAAGAAGAGGAAGAAGAGGAAGAGGAAGAGGAAGA 292931 
 
 
Organism: H. sapiens   
Query Gene: NOTCH1   
Subject 
Organism: C. lupus   
Subject 
Chromosome: 9     
Sequence Starting Position Sequence Ending Position 
Query 454 GGTGGCCAGTGCCTGCCCTTCGAGGCCTCCT 484 
Sbjct 971362 GGTGGCCAGTGACAGCCCACCGAGGCCTCCT 971332 
 
 
Organism: H. sapiens   
Query Gene: NOTCH1   
Subject 
Organism: M. musculus   
Subject 
Chromosome: 2     
Sequence Starting Position Sequence Ending Position 
Query 2032 AACATCGATGAGTGTGCGGGCAACCCCTGCCACAACGGGGGCACCTGCGAGGACGGCATC 2091 
Sbjct 10418837 AACATTAATGAGTGTGTGAGCAACCCCTGTTTGAATGGAGGGACCTGTATTGATGGTGTC 
1041877
8 
Query 2092 AATGGCTTCACCTGCCGCTGC 2112 
Sbjct 10418777 AACGGCTTCACCTGCGACTGC 10418757 
 
 
Organism: H. sapiens   
Query Gene: NOTCH1   
Subject 
Organism: R. norvegicus   
Subject 
Chromosome: 3     
Sequence Starting Position Sequence Ending Position 
Query 8948 TTTAAAAAATCTT-AATGAATGAGTCT 8973 
Sbjct 145117 TTTAATAAATCTTTAATGAATGAGTCT 145143 
 
 
Organism: H. sapiens   
Query Gene: PAX5   
Subject 
Organism: C. lupus   
Subject 11     
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Chromosome: 
Sequence Starting Position Sequence Ending Position 
Query 2369 TTTTCCAGATCAAAGAACTCA 2389 
Sbjct 6430123 TTTTCCAGATCAAAGAACTCA 6430103 
 
 
Organism: H. sapiens   
Query Gene: PAX5   
Subject 
Organism: M. musculus   
Subject 
Chromosome: 4     
Sequence Starting Position Sequence Ending Position 
Query 7731 acacacacacacacacacacacacac--acacacacacTCACTCACTCCCCTACACCTCA 7788 
Sbjct 41475914 ACACAATCACATATACACTCACACACTTATACATACACTCACACACTCTGATAT---TAG 41475858 
Query 7789 GACATACTTGAAACTCAGAAACAGCACTGAGTCTCCCCATGCCAATTCTTGCCTGCTGTC 7848 
Sbjct 41475857 GACAT----GAAACTCAGAAGAACTGCTGAGTATGCCAATGCCAGCTCTTGCTGGCTTTC 41475802 
Query 7849 TTCGACTTGGGTCAGAGAAGGTGAGCAGACCCGGCAGCAGCCTGTCCCGGGGCTCAGGAA 7908 
Sbjct 41475801 CTTGCCTTTAGTCCCAGAAGGTAAGCA-ACCCAGCAGCAGCCTGTCCAGGGGCTCAGAAA 41475743 
Query 7909 GAGGCAGGCCCATCCCCTGGCCCCAAGCACCCAGCACAACAGAGGGTGGCGGGCAGTGAG 7968 
Sbjct 41475742 GGGAAAGAGCTGGCCCCCAGCCCTAAGCCACCAGCACAGT-GTGAGTAGTGGGCAATGGG 41475684 
Query 7969 GGCCTGGCGTTGCCTGGGCCCCACTTCTCAGCCCCAGCTGCTGGG----CCTCCAAGGTT 8024 
Sbjct 41475683 GGTCCGATGTTACCAGCATGCTTCTCCTCTGCCTG-GCTGCAGGGTCAACCCCCACTGT- 41475626 
Query 8025 GGGCTGAGGATGGAG--TTTTGGCTCTGGGTTTG-CCCTGACTCCTGCTGGAAGACGCTG 8081 
Sbjct 41475625 --GTTCAGGAGGTAGAATTTTGAC-CAGAGTGTGGCCCTGGCTCCTTCTGGACAATGCTG 41475569 
Query 8082 CCCTGGTTTTTCACCCTCTAGTGGCCTTG-GACATTGAGTATTTGTAGAAATGCAGATTA 8140 
Sbjct 41475568 CCCTGGTTTGTCACCCTCTAGTGGCCTTCAGACATTGAGTATTTGTAGAAATGAAGATTA 41475509 
Query 8141 CATTGCAAATGGAAACCTTTGCCAGGAAGACACATGCATTTTGCTTTTAATTCTTTGAGA 8200 
Sbjct 41475508 CATTCCTAG-GGAA--CTCTGCCAGGAAGACACATGGGGTTTGCTCTTCATTCTTTTAGA 41475452 
Query 8201 CATTTGATTTTGTCTTAGGGACTGACCTTTC-AGCATCAAAGAAATACAT--------AT 8251 
Sbjct 41475451 TGGTTAACCTTGTCCTAGGGACAGACCTTTCCAGCATCAAAGAAATACATTTCTACTGAT 41475392 
Query 8252 CTACTGTATCCGCCAAAGTTTGTGATGCCTGCATAGACGCTTACTTGTaaaaaaaaaaaa 8311 
Sbjct 41475391 CTACTGTATCCGCCAAAGTTTGTGATGCCTGCATAGACG----CTTGT--TAAAAAAAAT 41475338 
Query 8312 atacaaaaaaatacaaaaaaaccaacaacaaaaac--CACAATTGAATTGCCTTTGAAAG 8369 
Sbjct 41475337 ACAGAAAAAAAACCAACAAAA--AATAAATAAAACCACACAATTGAATTGCCTTTGAAAA 41475280 
Query 8370 TGGGAGATGATCTGTCTCCAACGGATTGaaaaaaaaaaaTGCTTCTTAAAAAATGTGTAT 8429 
Sbjct 41475279 TGGGAGACAATGTGTCTCCAACAGATTGAGAAACAAAAA-GCTTCTT-AAAAGTATGTAT 41475222 
Query 8430 GTTTTGTATTC--tttttttCTAGTAGAAAATAACTGACTTGAAATATTGGTGG--tttt 8485 
Sbjct 41475221 GTTTTATATTCTTTTTTTTTCTAGTAG-----AACTGACTTGAAATATTGGTGGCTTTTT 41475167 
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Query 8486 tttCTTAGTGACGTGTGTTGCTTTTGTGTGTAATAATATTTGAATGTAATTACAGCAGTG 8545 
Sbjct 41475166 TTTCTTAGTGATGTGTGTTGCTTTTGTGTGTGATAATATTTGAATGTAATTACAGCAGTG 41475107 
Query 8546 CCAATTTGCCAAAGATGTTGGACATAtttttcttttttggggaggagggcaggg-ctagg 8604 
Sbjct 41475106 CCAATTTGCCAAAGATGTTGGAC-TATTTTTCTTTTGTTGGGAGATGGGAAGGGACTGAG 41475048 
Query 8605 ggtgggacttgggagaaaacaggggtggggttttggtTTAAttttttttttacttttttt 8664 
Sbjct 41475047 GGTGGGACTTGGGAG-GGACTGGGATGGGATACTGGTTTAA--TTTTTTTTAATTTTTTT 41474991 
Query 8665 tCCTTGTCAAACCTGAAATTTGTGGCTTCCTTTTAAGTTAAATGGTTGACTGCAACACCT 8724 
Sbjct 41474990 TTCTTGTTGAATCTGGGATTTGTGGATTTATTTTAACTTAAA----TGACTGCCACATCT 41474935 
Query 8725 TTATTTTAGATTAGTTGGAGAAACATGCAATAAGATTGGCGTAGTTTCAATATCTGTGTG 8784 
Sbjct 41474934 TTATTTTAAATTAGCAGGAGAAACATGCAATAAGA--CGCGTAGTTTCAATA--TATATG 41474879 
Query 8785 TCTTTTCATGAGTGGCTGTTACTTGTGAAGAATTGATTTTATGTAACCTTTATGTGAGAT 8844 
Sbjct 41474878 TCTTTTCATGAGTGACTGTCCCTTGTGAAGAATTGATTTTATGTAACCTTTATGTGAGAT 41474819 
Query 8845 AATTATTTGTAAATATTTGCCATAATTTTATTGGTTCCTAAAATAAAAGTAATTTTTTAA 8904 
Sbjct 41474818 AATTATTTGTAAATATTTGCCATAATTTTATTGGTTTCTAAAATAAAAGTAATTTTTTAA 41474759 
Query 8905 GTTCA 8909 
Sbjct 41474758 GTTCA 41474754 
 
 
Organism: H. sapiens   
Query Gene: PAX5   
Subject 
Organism: R. norvegicus   
Subject 
Chromosome: 11     
Sequence Starting Position Sequence Ending Position 
Query 7630 TAAAAAGAAAATAAATAAATC 7650 
Sbjct 18578 TATAAATAAAATAAATAAATC 18558 
 
 
Organism: H. sapiens   
Query Gene: PDGFRB   
Subject 
Organism: C. lupus   
Subject 
Chromosome: 4     
Sequence Starting Position Sequence Ending Position 
Query 3674 GAACCAGAGCCAGAGCCCCAGCTTGAGCTCCAGGTGGAGCCGGAGCCAGAGCTGGA 3729 
Sbjct 999195 GAGCCGGAGCCGGAGCCCGAGCCGGAGCCCGAGCCGGAGCCGGAGCCCGAGCCGGA 999140 
 
 
Organism: H. sapiens   
Query Gene: PDGFRB   
Subject M. musculus   
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Organism: 
Subject 
Chromosome: 18     
Sequence Starting Position Sequence Ending Position 
Query 503 CTCAAAGGCGAGCTGCTGTTGCTGTCTCTCCTGTTA---CTTCTGGAACCACAGATCTCT 559 
Sbjct 58061198 CTCAAAGGCCAGTTG---TTGCTGTC---CGTGTTATGGCTCCTGGGACCGCAGACCTCC 58061251 
Query 560 CAGGGCCTGGTCGTCACACCCCCGGGGCCAGAGCTTGTCCTCAATGTCTCCAGCACCTTC 619 
Sbjct 58061252 CGGGGCCTAGTCATCACGCCCCCTGGGCCAGAGTTTGTTCTCAACATCTCCAGCACCTTT 58061311 
Query 620 GTTCTGACCTGCTCGGGTTCAGCTCCGGTGGTGTGGGAACGGATGTCCCAGGAGCCCCCA 679 
Sbjct 58061312 GTTCTGACCTGCTCGGGCTCAGCTCCGGTGATGTGGGAACAGATGTCCCAGGTGCCCTGG 58061371 
Query 680 CAGGAAATGGCCAAGGCCCAGGATGGCACCTTCTCCAGCGTGCTCACACTGACCAACCTC 739 
Sbjct 58061372 CAAGAAGCGGCCATGAATCAGGACGGCACCTTCTCCAGTGTGCTGACACTGACCAATGTC 58061431 
Query 740 ACTGGGCTAGACACGGGAGAATACTTTTGCACCCACAATGACTCCCGTGGACTGGAGACC 799 
Sbjct 58061432 ACTGGGGGAGACACTGGGGAATACTTTTGTGTCTACAACAACTCACTAGGGCCGGAGCTC 58061491 
Query 800 GATGAGCGGAAACGGCTCTACATCTTTGTGCCAG 833 
Sbjct 58061492 AGTGAGAGGAAGCGTATCTATATCTTTGTGCCAG 58061525 
 
 
Organism: H. sapiens   
Query Gene: PDGFRB   
Subject 
Organism: R. norvegicus   
Subject 
Chromosome: 18     
Sequence Starting Position Sequence Ending Position 
Query 3674 GAACCAGAGCCAGAGCCCCAGCTTGAGCTCCAGGTGGAGCCGGAGCCAGAGCTGGAACAG 3733 
Sbjct 3839104 GAGCCAGAGCCAGAGCCGGAGCCAGAGCGAGAGCCGGAGCCGGAGCCGGAGCCGGAGCCG 3839045 
Query 3734 TTGCCGGA 3741 
Sbjct 3839044 GAGCCGGA 3839037 
 
 
Organism: H. sapiens   
Query Gene: PTEN   
Subject 
Organism: C. lupus   
Subject 
Chromosome: 26     
Sequence Starting Position Sequence Ending Position 
Query 3675 ttttttttttttttttttttttttttttAAATGTGCAGTGTTGAATCATTTCT 3727 
Sbjct 12932500 TTTTTTTTTTTTTTTTTTTTTTTTTTGCAGAAAACTACTGTAGAATCATTTCT 12932552 
 
 
Organism: H. sapiens   
Query Gene: PTEN   
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Subject 
Organism: M. musculus   
Subject 
Chromosome: 19     
Sequence Starting Position Sequence Ending Position 
Query 3660 TTGAAAGAATAGGGtttttttttttttttttttttttttttttAA 3704 
Sbjct 1541475 TTGAAAGAATATTAAAGTTTCTCTTTTTTTTTTTTTTTTTTTAAA 1541431 
 
 
Organism: H. sapiens   
Query Gene: PTEN   
Subject 
Organism: R. norvegicus   
Subject 
Chromosome: 1     
Sequence Starting Position Sequence Ending Position 
Query 5037 TCAAATGTTTCAGCTTTAAAAAATAAAA 5064 
Sbjct 10297687 TCAAGTGTTTCTGGTTTAAAAAATAAAA 10297714 
 
 
Organism: H. sapiens   
Query Gene: RECQL4   
Subject 
Organism: C. lupus   
Subject 
Chromosome: 13     
Sequence Starting Position Sequence Ending Position 
Query 3775 TCCAAAATGCAGAATAAAAAATGCTCACTTTGTTTTTAT 3813 
Sbjct 9923140 TCCAAAATGCAGAATAAATAAATCTCACTTATTTTTCAT 9923178 
 
 
Organism: H. sapiens   
Query Gene: RECQL4   
Subject 
Organism: M. musculus   
Subject 
Chromosome: 15     
Sequence Starting Position Sequence Ending Position 
Query 2400 GCTGCATCTGGGGCTGCCCCCAAGCT 2425 
Sbjct 753701 GCTGCATCTGGGTATGTCCCCAAGCT 753726 
 
 
Organism: H. sapiens   
Query Gene: RECQL4   
Subject 
Organism: R. norvegicus   
Subject 
Chromosome: 7     
Sequence Starting Position Sequence Ending Position 
Query 2467 GGGCAGCCTGCCCACTGCCACCTCTTCCTGCAG 2499 
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Sbjct 2802141 GGGCAGCCA--CCTCTGCCACCTCTGCCTGCAG 2802171 
 
 
Organism: H. sapiens   
Query Gene: STK11   
Subject 
Organism: C. lupus   
Subject 
Chromosome: 20     
Sequence Starting Position Sequence Ending Position 
Query 2672 GGCGGGCGTGGGAGGAGGGAGGCGGCCTCCATG 2704 
Sbjct 4085628 GGCGGGCGTGGGAGGAGGGACG-GGCCGCCCTG 4085597 
 
 
Organism: H. sapiens   
Query Gene: STK11   
Subject 
Organism: M. musculus   
Subject 
Chromosome: 10     
Sequence Starting Position Sequence Ending Position 
Query 2886 cattttctttttttctttttttttttAAGAAAAAATAAAAGG 2927 
Sbjct 239377 CAATTTCTTTTTTT---TTTTTTCTAAATACAAAATAAAAGG 239339 
 
 
Organism: H. sapiens   
Query Gene: STK11   
Subject 
Organism: R. norvegicus   
Subject 
Chromosome: 7     
Sequence Starting Position Sequence Ending Position 
Query 3138 ATATTTATATCATCCAGAAAAGAAAAACAC 3167 
Sbjct 6033661 ATATTCATATTATCCTGGAAAGAAAAACAC 6033632 
 
 
Organism: M. musculus   
Query Gene: AKT1   
Subject 
Organism: H. sapiens   
Subject 
Chromosome: 14     
Sequence Starting Position Sequence Ending Position 
Query 1326 AGGTGCTGGAGGACAACGACTACGGCCGTGCAGTGGACTGGTGGGGGCTGGGCGTGGTCA 1385 
Sbjct 86177479 AGGTGCTGGAGGACAATGACTACGGCCGTGCAGTGGACTGGTGGGGGCTGGGCGTGGTCA 
8617742
0 
Query 1386 TGTACGAGATGATGTGTGGCCGCCTGCCCTTCTACAACCAGGACCACGAGAAGCTGTTCG 1445 
Sbjct 86177419 TGTACGAGATGATGTGCGGTCGCCTGCCCTTCTACAACCAGGACCATGAGAAGCTTTTTG 
8617736
0 
Query 1446 AGCTGATCCTCATGGAGGAGATCCGCTTCCCGCGCACACTCGGCCCTGAGGC 1505 
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CAAGTCCC 
Sbjct 86177359 AGCTCATCCTCATGGAGGAGATCCGCTTCCCGCGCACGCTTGGTCCCGAGGCCAAGTCCT 
8617730
0 
Query 1506 TGCTCTCCGGGCTGCTCAAGAAGGACCCTACACAGAGG 1543 
Sbjct 86177299 TGCTTTCAGGGCTGCTCAAGAAGGACCCCAAGCAGAGG 86177262 
 
 
Organism: M. musculus   
Query Gene: NF1   
Subject 
Organism: H. sapiens   
Subject 
Chromosome: 17     
Sequence Starting Position Sequence Ending Position 
Query 9519 TAGCTCTTTCCATTGGCTCC 9538 
Sbjct 68448 TAGCTCTTTCCACTGGCTCC 68429 
 
 
Organism: M. musculus   
Query Gene: TRP53   
Subject 
Organism: H. sapiens   
Subject 
Chromosome: 17     
Sequence Starting Position Sequence Ending Position 
Query 104 CAGGCCCTCATCCTCC 119 
Sbjct 232646 CAGGCCCTCATCCTCC 232661 
 
 
Organism: R. norvegicus   
Query Gene: CCND1   
Subject 
Organism: H. sapiens   
Subject 
Chromosome: 11     
Sequence Starting Position Sequence Ending Position 
Query 1984 TGGgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtCGGTGGGGGAG 2043 
Sbjct 28805273 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGGTCGGGGGAG 28805332 
Query 2044 GGGG 2047 
Sbjct 28805333 GGGG 28805336 
 
 
Organism: R. norvegicus   
Query Gene: EGFR   
Subject 
Organism: H. sapiens   
Subject 
Chromosome: 7     
Sequence Starting Position Sequence Ending Position 
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Query 3421 GAATATATAAACCAATCTGTTCCCAAGAGGCCGGCTGGCTCTGTGCAGAACCCAGTCTAT 3480 
Sbjct 55195255 GAATACATAAACCAGTCCGTTCCCAAAAGGCCCGCTGGCTCTGTGCAGAATCCTGTCTAT 55195314 
Query 3481 CACAATCAGCCCCTGCATCCAGCTCCTGGAAGAGACCTGCATTATCAAAATCCCCATAGC 3540 
Sbjct 55195315 CACAATCAGCCTCTGAACCCCGCGCCCAGCAGAGACCCACACTACCAGGACCCCCACAGC 55195374 
Query 3541 AATGCGGTGAGCAACCCTGAGTATCTCAACACTGCCCAGCCGACCTGCCTCAGTAGTGGG 3600 
Sbjct 55195375 ACTGCAGTGGGCAACCCCGAGTATCTCAACACTGTCCAGCCCACCTGTGTCAACAGCACA 55195434 
Query 3601 TTTGACAGCTCTGCCCTCTGGATCCAGAAAGGCAGCCACCAAATGAGCCTGGACAACCCT 3660 
Sbjct 55195435 TTCGACAGCCCTGCCCACTGGGCCCAGAAAGGCAGCCACCAAATTAGCCTGGACAACCCT 55195494 
Query 3661 GACTACCAGCAGGACTTCTTTCCCAAAGAAGCCAAGCCGAATGGCATCTTTAAGGGCCCC 3720 
Sbjct 55195495 GACTACCAGCAGGACTTCTTTCCCAAGGAAGCCAAGCCAAATGGCATCTTTAAGGGCTCC 55195554 
Query 3721 ACAGCTGAAAATGCAGAGTACCTGCGGGTGGCACCGCCAAGCAGTGAGTTTAGTGGAGCA 3780 
Sbjct 55195555 ACAGCTGAAAATGCAGAATACCTAAGGGTCGCGCCACAAAGCAGTGAATTTATTGGAGCA 55195614 
Query 3781 TGACATTGAAGAGGCATTGTACCAG---TTACAAACCGGACTTTCCAGAGGCCCAGGACC 3837 
Sbjct 55195615 TGACCACG--GAGG-ATAGTATGAGCCCTAAAAATCCAGACTCTTTCGATACCCAGGACC 55195671 
Query 3838 AAGCCATGGCAGCACCTCTGCTCCTGACAGCCATGTCCACATTGTGTCAAATGTCAAACC 3897 
Sbjct 55195672 AAGCCACAGCAGGTCCTC-CATCCCAACAGCCATGCCCGCATT-----AGCTCTTAGACC 55195725 
Query 3898 CTCAGACTGGCTTTAAAGCATAACTCTGACGGGCTTTGTCACTG---AGCCAAGAAGTGG 3954 
Sbjct 55195726 CACAGACTGGTTTT---GCA--------ACG----TTTACACCGACTAGCCAGGAAGT-- 55195768 
Query 3955 GCCCCTCC-CCTGATGCTC--TTTGGGAAGTTGAAGGTATATCTATTGGTCTTCGAACTG 4011 
Sbjct 55195769 --ACTTCCACCTCGGGCACATTTTGGGAAGTTG------CATTCCTTTGTCTTCAAACTG 55195820 
Query 4012 TGAAGATTCCACTGAAAGGTATCCATCGAGAACATTGTCCTTTTGGAACAGAA 4064 
Sbjct 55195821 TGAAGCATTTACAGAAACGCATCCAGCAAGAATATTGTCCCTTT-GAGCAGAA 55195872 
 
 
Organism: R. norvegicus   
Query Gene: NGF   
Subject 
Organism: H. sapiens   
Subject 
Chromosome: 1     
Sequence Starting Position Sequence Ending Position 
Query 737 AGAGAGTGGATGCCGGGG 754 
Sbjct 11279 AGAGAGTGGATGCCGGGG 11262 
 
